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Summary 
 
 
 
 
 
 
 
 
 
 
 
 
Sphingolipids (SLs) are cell membrane amphiphilic components, which reside 
in the external layer of the plasma membrane (PM), with the hydrophobic 
moiety, the ceramide (Cer), inserted into the membrane layer and the 
hydrophilic head group protruding toward the extracellular environment. As 
membrane components, SLs participate to modulate several cell processes, 
such as cell growth, motility, differentiation, morphogenesis, cell to matrix 
interaction and cell to cell communication. From this, it follows that a defect 
in SL metabolism can obviously lead to a great number of dysfunctions, 
ranging from neurodegeneration to cancer.  
During my PhD course, I studied the different faces of SLs in cancer 
malignancy. In particular, I focused my attention on the involvement of SL as 
well as of their metabolism in the prostate and bladder cancer malignancy 
and in their response to the conventional therapies.  
As well known, prostate cancer (PC) is the most common malignancy and 
second leading cause of cancer-related death in men. It is generally treated 
with radiotherapy and androgen ablation even if the onset of resistance is 
very frequent. Abiraterone is a new promising drug recently approved for the 
treatment of PC that seems to reduce this drawback inducing cell death also 
in androgen-resistant PC, nevertheless it mechanism of action is almost 
unknown. It is nowadays accepted that several pharmacological treatment as 
well as radiotherapy induce the ceramide-mediated apoptosis through the 
activation of the PM-associated SL-hydrolyses that generate in situ the 
formation of pro-apoptotic ceramide.  
Based on these findings, this study addresses whether these enzymes are a 
target of abiraterone and of ionizing radiation in human PC. To this purpose, 
androgen-sensitive and androgen-insensitive PC cell lines were subjected to 
treatments with abiraterone and/or ionizing radiation and the activities of 
different PM-associated glycohydrolases as well as the ceramide level were 
evaluated. Interestingly, all the cell lines tested showed a marked increase in 
all the PM-associated glycohydrolases as well as in their ceramide content, 
especially after the combined treatment with abiraterone and ionizing 
radiation. These data demonstrate the involvement of the glycohydrolases in 
the mechanisms of abiraterone- and radiation- induced cell death in both 
androgen sensitive and insensitive PC cells and suggest that these enzymes, 
able to evocate the production of ceramide at the PM-level, could represent 
new potential therapeutic targets for prostate cancer. 
Otherwise, part of my study are related to the involvement of the SL in the 
bladder cancer cell death induced by the treatment with antagonists of the 
cannabinoid receptor 2. 
Bladder cancer (BC) is the most severe malignancy form of the genitourinary 
tract. Clinically, 75-80% of bladder neoplasms correspond to non-muscle-
invasive bladder cancer (NMIBC) at diagnosis. After transurethral resection of 
the tumor followed by adjuvant chemotherapy, 30 to 50% of patients recur, 
and more than 15% of those undergo progression to muscle-invasive disease. 
Identification of novel potential targets to reduce recurrence and prevent 
disease progression represents a medical challenge for bladder cancer. 
Among the various putative novel biomarkers or targets recently described 
for urothelial carcinoma, the endocannabinoid system (ECS), expressed by 
the genitourinary organs, has recently gained particular attention. The ECS 
components such as CB1-CB2 receptors, and the endocannabinoid-
degrading enzyme fatty acid amide hydrolase (FAAH) are present in the 
bladder at the epithelial level and play a role in regulating its functions. As 
recently shown, both clinical and experimental evidence has indicated a 
possible role of the ECS in modulating cancer proliferation, progression and 
metastasis in several types of neoplastic diseases, including, prostate and 
breast cancer. Interestingly, few information are available on the possible role 
of ECS components in proliferation and metastasis of human urothelial 
carcinoma, or on the mechanisms underlying progression to the muscle 
invasive phenotype. In this context, glycosphingolipids (GSL) play an 
important role. Indeed, aggressive, muscle-invasive BC is characterized by a 
different expression of the GM3 and Gb3 glycolipids, suggesting that the 
metabolism of GSL plays a role in controlling cell invasion and motility. 
Similarly, the known antiproliferative activity of cannabinoids in cancer 
models is reported to involve changes in GSL metabolism with accumulation 
of ceramide (Cer) via de novo synthesis and putative deregulation of the Cer/ 
sphingosine-1-phosphate (S1P) rheostat. Otherwise, the plasma membrane-
associated enzymatic hydrolysis of GSL is activated and produces a signaling 
cascade that may modulate cytoskeletal changes via p-ERM and cell 
migration via Src. Into this picture though, it’s important also to consider the 
already reported receptor-independent effects of cannabinoids, which may 
play an important role in our system. In my study I show a strong 
associations between the anti-metastatic properties of cannabinoids and GSL 
metabolism. This finding, together with the in vitro antiproliferative effect, the 
in vivo efficacy on tumor progression, and the tumor-specific up-regulation of 
CB2 in primary bladder cancer may play a role in the identification of novel 
therapeutic and diagnostic targets for treating bladder cancer.  
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12 State of the Art 
Sphingolipids 
Sphingolipids (SL) are amphiphilic molecules residing in the external layer of the 
plasma membrane (PM) of mammalian cells [1] consisting in a hydrophobic 
moiety, ceramide (Cer), and in a hydrophilic headgroup from different origin. Cer 
is the most simple SL composed by a long chain amino alcohol like the 2-amino-
1,3-dihydroxyoctadec-4-ene (sphingosine), connected to a fatty acid by an amide 
linkage. Of the four possible configuration of sphingosine, only the 2S,3R is 
present in nature [2,3]. Cer is the common precursor of complex SLs, which are 
synthesized by addition of polar molecules to the hydroxyl group in position 1 of 
the sphingoid base [4]. 
 
 
 
Figure 1. Structure of ceramide and sphingosine. 
 
Hundreds of SL molecular species, differing in their polar head group, sphingoid 
base and fatty acyl moiety, have been described. Referring to the polar head 
group there is the phosphocholine, component of sphingomyelin (SM), and a very 
wide group of oligosaccharide chains, components of glycosphingolipids (GSLs) 
[5]. GSLs containing one or more sialic acid residues in the carbohydrate chain 
are referred to as gangliosides. Based on the sequences of the carbohydrate core 
residues, GSLs are classified into a number of series (including gala-, ganglio-, 
isoganglio-, lacto-, neolacto-, lactoganglio-, globo-, isoglobo-, and muco-series). 
Structural diversity in their carbohydrate chains is a hallmark of GSLs. At 
present, 172 neutral GSLs, 24 sulfated GSLs and 188 gangliosides with 
variations in the carbohydrate chain have been reported in a variety of vertebrate 
tissue and organs [6]. This complexity is increased many fold when heterogeneity 
in the lipophilic components is taken into consideration. 
The glycolipids are clearly significant contributors to the structure of the outer 
leaflet of most eukaryotic cell membranes. The molar ratio of these molecules 
relative to the other major membrane lipids (phospholipids, cholesterol and 
glycerolipids) varies from being <0.5% in erythrocytes to about 6% in neurons. 
Thus, in neurons, SL are about the 12% of total lipids of external PM layer.  
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Sphingolipids neobiosynthesis 
Sphingolipid biosynthesis in eukaryotic cells requires: 
1) the intracellular formation of the membrane anchor ceramide [7];  
2) The sequentially addition of the single carbohydrate residues or of the methyl 
choline [8-9].  
 
Ceramide and Sphingomyelin neobiosynthesis 
The begginig of the synthesis of the sphingoid bases (sphingosine, 
dihydrosphingosine) takes place via the condensation of palmitoyl-CoA and serine 
as shown in the Figure 2. This reaction occurs on the cytoplasmic face of the 
endoplasmic reticulum (ER) and is catalyzed by the pyridoxalphosphate-
dependent enzyme, serine palmitoyltransferase (SPT). The product of this 
reaction is 3-ketosphinganine (3-ketodihydrosphingosine). SPT is the rate-limiting 
enzyme of the sphingolipid biosynthetic pathway; an additional protein 
associates with the catalytic subunits to greatly enhance the activity of the 
enzyme complex as well as to confer acyl-CoA preference to the complex. 
Following formation of 3-ketosphinganine this compound is reduced to 
sphinganine (dihydrosphingosine) via the action of 3-ketosphinganine reductase 
(3-ketodihydrosphingosine reductase)[10-12]. Sphinganine is then acylated 
generating dihydroceramide. The acylation of sphinganine (also called 
dihydrosphingosine) occurs through the activities of six different ceramide 
synthases (CerS) in humans. These CerS enzymes introduce fatty acids of 
varying lengths [designated by the –(CH2)n– in the structure] and degrees of 
unsaturation [13-15]. Dihydroceramide is then unsaturated in ceramide by the 
enzyme dihydroceramide desaturase 1 (DES1)[16-18]. The official designation for 
DES1 is delta(4)-desaturase, sphingolipid 1 which is encoded by the DEGS1 gene 
located on chromosome 1q42.11 that is composed of 5 exons encoding a protein 
of 323 amino acids. 
The neo-synthesized ceramide could reach directly the membrane or it is used as  
common precursor for glycosphingolipids (GSL) or sphingomyelin (SM) 
biosynthesis. In both cases the ceramide reaches the Golgi apparatus by a not 
well defined mechanism [19], able to selectively address the synthesis of SM or 
GSLs. SM neobynthesis occurs via addiction of phosphocholine group to the 
hydroxyl group in position 1 of the sphingoid base of the ceramide.  
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Figure 2. De novo ceramide biosynthesis. 
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Cer is also generated during the catabolism of SLs that occurs in lysosomes, and 
rapidly converted to sphingosine which is largely recycled. Cer synthase is able to 
use as substrate both sphingosine and sphinganine with similar efficiency [23-
25], so Cer can be also formed by N-acylation of sphingosine produced by the 
catabolism of complex sphingolipids (Figure 3). 
 
 
 
 
Figure 3. Ceramide from catabolism 
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Glycosphingolipid neobiosynthesis 
Glucosylceramide (GlcCer) is the most common GSL precursors, formed by a 
ceramide glucosyltransferase activity localized at the cytosolic side of the early 
Golgi membrane [20]. Glucosylceramide can either directly reach the plasma 
membrane [21], presumably transported in a non-vesicular manner [REF], or be 
translocated to the luminal side of the Golgi, where it is further glycosylated by 
other glycosyltransferases to generate more complex glycosphingolipids. 
Lactosylceramide (LacCer), is formed by the addiction of a galactose moiety from 
UDP-Gal to GlcCer, catalyzed by galactosyltransferase. LacCer formation and 
also the reaction leading to higher glycosylated lipids occur on the luminal leaflet 
of Golgi membranes [22]; neo-synthesized GSLs move through the Golgi 
apparatus to the plasma membrane following the mainstream exocytotic 
vesicular traffic. 
The biosynthesis of sialic acid-containing GSLs, the gangliosides, is catalyzed by 
glycosyltransferase in the lumen of the Golgi apparatus starting from the 
common precursors LacCer [8, 26, 27]. on the other hand the gangliosides GM3, 
GD3 and GT3, serve as precursors for the complex gangliosides of the 0-, a-, b-, 
and c-series (Figure 4). In adult human tissues, gangliosides from the o- and c-
series are found only in trace amounts. The transferases which catalyze the first 
steps in ganglioside biosynthesis show high specificity towards their glycolipids 
substrates, i.e. for the formation of LacCer, GM3 and GD3. The relative amount 
of these GSLs in the steady state seems to determine the amount of o-series 
GSLs, which are derived only from LacCer, a-series gangliosides which are only 
derived from the ganglioside GM3, and b-series gangliosides which are only 
derived from ganglioside GD3. Sialyltransferase I and II are much more specific 
for their glycolipids substrates than sialyltransferases IV and V, or than 
galactosyltransferase-II and GalNAc transferase. It was assumed that different 
transferases catalyze the formation of homologous gangliosides of different series. 
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Figure 4. Scheme of Gangliosides biosynthesis. The formation of 0, a, b and c-series 
gangliosides is catalyzed by glycosyltransferases of Golgi membranes; all the enzymatic steps (except 
LacCer formation) take place at the luminal surfaces of the Golgi membranes. 
“G” denotes “ganglioside”, “A” denotes “asialo” or lacking sialic acid; “M” denotes “monosialo”, 
“D” denotes “disialo” and the numbers indicate the carbohydrate sequence. Cer: ceramide; GlcCer: 
glucosylceramide; LacCer: lactosylceramide; GalNAc: N-acetylgalactosamine [143]. 
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Catabolism 
Another important point of regulation of plasma membrane SLs composition is 
the lipidic degradation which occurs in the lysosomes, where the SLs are 
transported by the endocytic vesicular flow through the early and late endosomal 
compartment to be catabolyzed (Figure 9). 
Lysosomal glycosidases sequentially cleave the sugar residues from the non-
reducing end of their glycolipid substrates. The resulting monosaccharides, sialic 
acids, fatty acids and sphingoid bases can leave the lysosomes and recycled or 
can be further degraded. In addition, the intra-lysosomal degradation of most, if 
not all, GSLs requires cofactors called “sphingolipid activator proteins (SAPs, or 
saposines)” [28].  Using the ganglioside GM1 as example of a GSLs lysosomal 
degradation, the first step is the removal of the galactose by the β-Galactosidase 
together with the GM2-AP or SAP-B [29], yielding GM2 (Figure 5). 
 
 
Figure 5. Reaction catalyzed by β-Galactosidase 
 
The resulting gangliosides GM2 is catabolized to ganglioside GM3 and N-
acetylgalactosamine by the β-Hexosaminidase isoenzymes Hex-A and GM2-AP 
(Figure 6). 
 
 
Figure 6. Reaction catalyzed by β-Hexosaminidase A. 
 
In some cells and animals, sialic acid is removed from GM1 and GM2 by a 
specific sialidase (GM1 and GM2-sialidase) producing the corresponding a-sialo 
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derivatives GA1 and GA2, that, by the action of β-Galactosidase and β-
Hexosaminidase or only β-Hexosaminidase respectively, are converted to LacCer. 
LacCer is produced also directly from GM3 by the action of a sialidase which 
cleaves this gangliosides into LacCer and sialic acid a reaction stimulated by 
SAP-B (Figure 7)[30]. 
 
  
Figure 7. Reaction catalyzed by sialidases. 
 
LacCer is then degraded to Cer by the sequential action of a β-Galactosidase (in 
the presence of either SAP-B or –C) and β-Glucosidases GBA1 and GBA2 (Figure 
8)[31]. 
 
 
Figure 8. Reaction catalyzed by β-Glucosodase GBA1 and GBA2. 
 
Cer is cleaved by acid ceramidase in the presence of SAP-D [32] into sphingosine 
and fatty acid. Together with the other cleavage products, there two metabolites 
are able to leave the lysosomes. An alternative pathway for ganglioside/GSLs 
degradation is the splitting of β-glucosidic linkage between glucose and Cer, with 
the formation of Cer and the oligosaccharide. The enzymes catalyzing this 
reactions, named “endoglycoceramidase” or “Cer glycanases” [33-38] appear to 
require, or to be markedly activated, by a specific activator proteins whose action 
would be essential in vivo conditions [33]. Endoglycoceramidases have been 
found to occur in some bacteria [33] and leeches [34]. Although described to 
occur in lactating mammary glands of rodents [36], the presence of this enzyme 
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in vertebrate and, particularly, mammalian tissues is yet to be definitely 
assessed. For the non-glycosylated SLs, like Cer and SM, non-lysosomal 
degradation steps are known which apparently do not need the assistance of an 
activator protein. SM is cleaved to Cer and phosphorylcholine; Cer later on is 
degraded into sphingosine and a fatty acid by ceramidase. Sphingosine moves 
into the cytosol where it can be phosphorylated to sphingosine-1-phosphate and 
further degraded to phosphoethanolamine and long chain aldehyde. But at the 
same time sphingosine-1-phosphate acts as metabolic regulator [39]. 
Enzymes that are capable to remove the fatty acid moiety from several 
sphingolipids (SM, gangliosides and some neutral GSLs) producing the 
corresponding lyso-derivatives were also described [39,40]. These enzymes, 
known as SL Cer N-deacylases, were detected in bacteria; no evidence was yet 
provided for their occurrence in vertebrates, however, it is known that in the 
brain of patients suffering from some sphingolipidosis where there is 
accumulation of lyso-GSLs [41], these accumulated compounds seems to be the 
products of proteins having this kind of enzymatic activity. 
 
 
Figure 9. Intracellular sphingolipid metabolism and trafficking. 
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The regulation of GSL composition at the plasma membrane level 
Changes in the GSL composition of the plasma membrane in a certain cell type 
would lead to very important biological consequences, this all mechanisms 
possibly contributing to these changes have a high functional significance. The 
classical view on sphingolipid metabolism implies the vesicular transport of neo-
biosynthesized sphingolipids from the endoplasmic reticulum and the Golgi 
apparatus to the plasma membranes [47]. Changes in the activities of enzymes of 
the biosynthetic pathway have been associated with the changes in GSL 
expression which are associated with biological events such as neoplastic 
transformation or neuronal differentiation. However, other mechanisms could be 
responsible for a local regulation of the GSL composition of plasma membranes 
or restricted plasma membrane areas (Figure 10). Both catabolic and 
biosynthetic enzymes for sphingolipids have been found associated with the 
plasma membranes. “Signalling” sphingomyelinases are resident in or 
translocated to the plasma membrane, being able to convert plasma membrane 
sphingomyelin into ceramide [48,49]. Conversely, a plasma membrane-associated 
sphingomyelin synthase enzyme activity (SMS2), genetically distinct from the 
Golgi enzyme, has been identified [50]. Thus, the sphingomyelinase/ceramide 
ratio can be locally modulated possibly in response to physiological events, 
leading to profound consequence on the organization of sphingolipid-enriched 
membrane areas. In the case of GSLs, a specific membrane-bound sialidase 
(Neu3) has been identified and cloned [51-53]. Neu3 can be considered an 
ubiquitous enzyme being expressed at different levels in all the PM of tested 
normal and pathological human tissues such as human brain [71] normal and 
colon rectal carcinoma tissue, hepatic tumor and kidney carcinoma [72-76]. In 
addition its expression and activity were also found in normal and pathological 
cell lines such as erytroid and erytroleukemic cells [77-79], human fibroblasts 
[80], rat and mouse neurons, neuroblastoma cells [81], human breast ductal 
cancer T47D cells, colon carcinoma CaCo2 cells, human colorectal 
adenocarcinoma HT29 cells, different type of ovarian cancer cells, human cervix 
adenocarcinoma HeLa cells [76]. It has been demonstrated the presence of Neu3 
in the lipid rafts and its co-localization with gangliosides: the non-random 
distribution of Neu3 at the cellular surface introduces the possibility that the 
biological effects of this enzyme might be due to the local reorganization of GSLs-
based signaling units. Remarkably, Neu3 is able to modulate the cell surface 
glycolipid composition because of trans interactions, thus modifying the surface 
of neighboring cells [55]. 
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Moreover, the presence of sialyltransferase activities at the cell surface has been 
also reported [57-61]. Thus, glycosylation/deglycosylation cycles might be very 
important mechanisms responsible for rapid and possibly transient changes of 
the plasma membrane GSLs composition, in analogy to that proposed for the 
“sphingomyelin cycle”. The presence of other active glycohydrolases, β-
Glucosidase, β-Galactosidase and β-Hexosaminidase [56-62], in the plasma 
membrane has been demonstrated, implying that local hydrolysis of GSL at the 
cell surface might represent a general mechanism for the control of GSL 
composition.  
 
 
 
Figure 10. Regulation of sphingolipid-enriched membrane domain composition by 
phosphorylation/dephosphorylation (“sphingomyelin cycle”) and glycosylation/ deglycosylation. 
The interconversion of ceramide and sphingomyelin due to the action of plasma-membrane resident 
sphingomyelinases and sphingomyelin synthase 2 leads to profound reorganization of the sphingolipid-
enriched membrane domains. In particular, ceramide generation can lead to changes in the membrane 
domains into large ceramide-rich signalling platform. GSL composition can be regulated by desilylation due 
to the plasma membrane.associated sialidase Neu3, and probably by membrane-resident glycosyltransferase, 
leading to changes in the geometry and organization of GSL-rich membrane domains and in specific GSL-
protein interactions. 
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The presence of β-Hexosaminidase A in the external leaflet of PM has been 
demonstrated in cultured fibroblasts [62]. Immunological and biochemical 
characterization of the membrane-associated β-Hex indicated that this enzyme 
has the same structure of that in lysosomes. PM associated β-Gal has been 
found in all cell lines studied for the activity of Neu3. In human fibroblasts its 
expression is up regulated by Neu3 [56].  
On the other hand, the β-galactosidase (β-Gal) activity was measured during 
neuronal cell differentiation and aging, in the total cell lysate and in the PM from 
rat cerebellar granule cells. Both these activities resulted up regulated during cell 
differentiation. As expected the β-Gal activity associated to the cell PMs was  less 
than the one found in the total cell homogenate. The total cell activity remained 
constant during differentiation, then increased 4 fold along aging in culture. 
Instead, cell surface activity increased 10 fold during differentiation, to then 
duplicate during the neuronal senescence [82]. β-Gal activity has been proposed 
as senescent marker of different cell lines [83-86]. The information on the 
behavior of PM associated enzyme in rat cerebellar granule cells suggests that its 
activity could be used as a good marker for both neuronal differentiation and 
neuronal aging. The identity of the protein, or proteins, responsible for the β-Gal 
activity present at the cell surface is still unknown, however in living human 
fibroblasts has been verified the presence of a β-Gal activity which displays a 
trans activity, with no necessity of detergents or activator proteins, on 
lactosylceramide (LacCer) immobilized on cell culture plates, suggesting that on 
the cell surface is present at least an enzyme having a β-galactocerebrosidase-
like activity [70]. 
Concerning β-Glucosidases, GBA2 has been found associated to endosome 
vesicles or to the PM, it is insensitive to CBE whereas is specifically inhibited by 
N-(5-adamantane-1-yl-methoxy)pentyl)-deoxynojirimycin (AMP-DNM) [89,90]. 
Recently it has been described that a CBE-sensitive β-Glc activity is present in 
the PMs [70]. Both CBE-sensitive and CBE-insensitive β-Glc enzymes were found 
associated to the cell surface of rat cerebellar granule cells in culture, where they 
progressively increase along the differentiation and the aging process [83]. 
Total β-Glc activity associated to the PMs of human living fibroblasts works on 
natural substrates in trans fashion [70] and the activity is connected to Neu3 
activity (like the β-Glc). In fact, in human fibroblasts over-expressing Neu3, the 
β-Glc activity associated to the PM was much higher of that found in normal 
fibroblasts. Surprisingly this is mainly due to an up-regulation of the CBE-
sensitive β-glucosidase [70].  
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Considering the presence of lysosomal glycohydrolases at the cell surface, two 
aspects need to be clarified: how lysosomal deriving enzymes can reach the PM 
and how they can be active at the cell surface where the pH conditions are far 
from those of the lysosomes. It is known that a regulated fusion of lysosomes 
with the PM may represent a general mechanism of repairing for the PM [99], and 
could be responsible of the presence of lysosomal enzymes facing at the cell 
surface. However this enzymatic “translocation” couldn?t be accidental and the 
fusion of lysosomal membranes with the PM could be the way for all the 
lysosomal glycolipid-metabolizing enzymes to reach the cell surface where, 
together with specific and different membrane associated enzymes, play an active 
role in remodeling the glycolipid content and pattern of the external leaflet of the 
PM. At the cell surface the pH conditions are usually considered near to the 
neutrality, whereas the lysosomal pH is much more acidic. For some 
glycohydrolases described associated to the PM has been evaluated the optimum 
of pH to which they play their catalytic activity. Both the β-Hex A and Neu3 
(respectively codified by the same and by a different gene with respect to the 
corresponding lysosomal enzyme) has been found working in acidic condition (pH 
4.45 and pH 4.2 respectively). This information suggests that modulation 
systems, able to modify the pH conditions, even locally, could be present at the 
cell surface. One hypothesis for this theory may be the action of proton pumps 
present at the PM level for which has already been demonstrated a role in the 
acidification of the tumor extracellular environment [100-102]. 
In addition to an active in situ modification due to specific enzymatic activity a 
further way to modify the lipid membrane domain composition and organization 
Is represented by a controlled release of GSL from the cell surface including 
shedding vesicle [63-65]. 
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Glycosylation and cancer malignancy 
Aberrant glycosylation, at the cell surface level, has been observed in essentially 
all type of human cancer. This event contributes to deep alterations in the 
interactions between tumor cells and the extracellular environment, which 
underline many of the features that defined several tumor phenotype, including 
self-sufficiency in growth signals, insensitivity to growth-inhibitor stimuli, 
evasion from programmed cell death (apoptosis), sustained angiogenesis, tissue 
invasion and metastasis (Figure 11) [67]. 
Alteration in glycan expression in cancer is usually a consequence of 
modification in the metabolic pathway of glycoconjugates, as a result of change 
in the biosynthesis, catabolism and intracellular trafficking of GSLs and 
glycoproteins.  
Like reported above, changes of the glycoconjugate oligosaccharide structures 
and in particular changes of GSLs, can be obtained at the cell surface by the 
activities of PM-glycohydrolases. Recent study indicate that the aberrant 
glycosylation could be a result of initial oncogenic phenomena, as well a key 
event for the induction of invasion and metastasis. 
 
 
 
 
Figure 11. Glycosylation defining malignancy (invasive and metastatic phenotype of 
tumors) (from [67]). 
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Membrane lipid domains 
The interest in membrane lipid domains, which is, in zones of the membrane 
with a peculiar lipid composition, different from that of the majority of bilayer, 
became very strong during the last 20 years, when many proteins assigned to cell 
signalling were found to be preferentially associated with an environment of 
lipids highly enriched in sphingolipids and cholesterol. A possible role for lipid 
domains in the transport of glycosylphosphatidylinositol (GPI)-anchored proteins 
from the Golgi apparatus to the apical plasma membrane of polarized cells was 
also suggested; hence, the use of the term “lipid rafts” to define this domains 
[103]. Biochemical studies on cell membrane lipid domains and composition, 
organization and biological role were carried out mainly starting from 1992, when 
a method capable of separating them from total cell membrane became available 
[102]. However, massive biophysical work on artificial membranes was carried 
out from the 1970s to understand the basis of the organization of aphiphilic 
compounds within biological membranes, leading to establishment of the 
existence of segregation phenomena. Today, different terms are used throughout  
the literature to define lipid membrane domains: every one of them implies a 
form of segregation of certain components within the cell membrane. Some define 
specific domains, as in the case of “caveolae”, membranes invaginations 
containing the protein caveolin [103], or “lipid rafts”, membrane domains that 
sort or transport proteins inside cells. Others define membrane portions on the 
basis of chemico-physical or compositional features, such as “DIM” (Detergent-
Insoluble Material), “DISAM” (Detergent-Insoluble Substrate Attachment Matrix) 
[104], “DIG” (Detergent-Insoluble Glycolipid-enriched material) [105], “SEMF” 
(Sphingolipid-Enriched Membrane Fraction) [106], “GSD” (Glyco-Signalling 
Domains) [107], etc. To this author, DRM is a very reasonable definition, based 
on the operational way commonly used to obtain biochemical preparation 
enriched in lipid membrane domains, which is based on their relative insolubility 
in nonionic detergents under specific experimental conditions. The existence of 
lipid membrane domains in natural cell membranes was suggested by the 
observation that glycosphingolipids at the cell surface form clusters, which have 
been visualized by immune-electron microscopy using anti-glycosphingolipid 
antibodies [108]. Glycosphingolipid clustering in cell membranes was shown for 
globoside in human erythrocytes [109], polysialogangliosides in fish brain 
neurons [110], GM3 ganglioside in peripheral human lymphocytes, and Molt-4 
lymphoid cells [111]. Several approaches, relying on more advanced technologies, 
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are now available allowing the detection and the study of membrane lipid 
domains in intact cell membranes [112,113]. These techniques are very 
heterogeneous and include single-particle tracking or single-fluorophore tracking 
microscopy [114-116], “FRAP” (Fluorescent Recovery After Photobleaching) [117], 
“FRET” (Fluorescence Resonance Energy Transfer) [118], and “AFM” (Atom Force 
Microscopy) [119], and data obtained with different approaches are sometimes 
conflicting. As an example, there is no agreement on their avegarge size, which 
ranges from 26 nm to about 2 μm [120]. In addition, from these data no 
information on that composes the lipid domains can be inferred. Compositional 
information for membrane lipid domains is largely obtained by means of the 
procedure published by Brown and Rose [121], based on the insolubility in 
aqueous nonionic detergents of those cell lipids (including cholesterol, 
sphingolipids and saturated PC) that in membrane models tend to segregate into 
a liquid-ordered phase. All the complex amphiphilic compounds that are 
components of cell membrane and several intrinsic membrane proteins can be 
solubilized by detergents, due to the formation of mixed aggregates. But, under 
certain experimental conditions, where low temperature, detergent concentration 
and detergent-to-cell ratio seem the most critical parameters, a part of the cell 
membrane remains insoluble in the nonionic detergent Triton X-100. Other 
detergents were used and claimed to be not capable of solubilizing membrane 
lipid domains [122-124]. After detergent treatment, the detergent-insoluble 
membrane fraction can be separated from the rest of the cell thanks to its 
relative light density (buoyancy) [125-129], using continuous or discontinuous 
sucrose density gradients. The low density of the detergent-insoluble material is 
due to the high lipid-to-protein ratio in the fraction. Low-density, detergent-
insoluble fractions were isolated from a wide variety of cultured cells, including 
almost all normal and pathological mammalian cell types investigated so far, as 
well as yeast [130] and protozoans [131]. In a second time, reports on the 
isolation on this fraction from tissue appared [132-136]. Membrane lipid domains 
contain all the cell complex lipids but are highly enriched in sphingolipids and 
cholesterol. Nevertheless, glycerophospholipids remain the bulk components, 
being enriched in phosphatidylcholine that being highly enriched in the 
dipalmitoyl species. These results were confirmed using other procedures where 
the detergent is substituted by an high pH, hypertonic sodium carbonate [137], 
or mechanical treatments (sonication under carefully controlled conditions) [138], 
followed by density gradient centrifugation to recover the light fraction. The 
general agreement on the sphingolipid and cholesterol enrichment in the low-
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density membrane fraction obtained with the above procedures, that is, under 
different experimental conditions, would prove that the isolated lipid membrane 
domains are not the result of a random rearrangement of cell components 
induced by the treatment but are a good mirror of an organization naturally 
occurring on the cell membranes. Of course, any change in the experimental 
conditions can yield quantitative changes of each component. Membrane lipid 
domains contains a small amount of proteins, in general no more than 05-2.5% 
of total cell proteins: however, proteins that are involved in the process of 
transduction of the information throughout the cell plasma membrane (including 
receptor and non-receptor protein tyrosine kinases, G protein coupled receptors, 
GTP binding proteins) result frequently enriched in the lipid domains. 
Scientist are making every effort to isolate different membrane lipid domains 
from the DRM fraction; immunoisolation procedures allowed fractionation of the 
DRM fraction into sub-populations with strikingly different structure and 
functions. Two membrane sub-fraction were separated from DRM isolated from 
B16 melanoma cells by anty-GM3 ganglioside monoclonal antibody DH2 and by 
anti-caveolin antibody [139]. The anti-GM3 sub-fraction was enriched in GM3 
and contained sphingomyelin, cholesterol and proteins c-Src and Rho A, but no 
caveolin, while the anti-caveolin sub fraction contained caveolin, 
glucosylceramide, sphingomyelin and a large amount of cholesterol, but no GM3, 
c-Src or Rho A. The GM3-enriched sub-fraction, but not the caveolar sub-
fraction, was involved in cell adhesion-dependent signal transduction in these 
cells. Two sub-populations, containing two functionally different neuronal GPI-
anchored proteins, Thy-1 and PrP [140], were separated from the detergent-
resistant fraction isolated from mouse brain. Immunoisolation approaches based 
on the use of different antibodies against protein or lipid components of the lipid 
membrane domain fraction might thus become the method of choice for the 
separation of lipid membrane domains, possibly overcoming some of the negative 
aspect of the classical density gradient flotation method after detergent lysis and 
allowing attainment of novel information about the properties of functionally and 
structurally different sub-populations of lipid membrane domains. The use of 
antibodies could however be responsible for art factual clustering induced by 
antibody bridging or cross-linking: hence caution should be exerted also in this 
case. 
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Figure 12. Membrane model containing different DRM. 
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Prostate cancer 
Prostate cancer (PC) is one of the most commonly diagnosed malignant tumors: 
in the United States, PC is the second leading cause of cancer-related death in 
men, and it is a growing problem worldwide [1]. The disease is very 
heterogeneous in terms of grade, genetics, ploidy, and oncogene/tumor 
suppressor gene expression, and its biological, hormonal, and molecular 
characteristics are extremely complex. Growth of early PC requires 5α-
dihydrotestosterone (DHT) produced from testosterone by the 5α-reductase 
enzyme system: such prostate cells are described as androgen-dependent (AD). 
Because prostate cancer exerts androgen-dependent growth, androgen ablation 
or anti-androgen therapies are very effective [2-4]. Androgen receptor (AR) 
antagonists including bicalutamide or flutamide are used as monotherapy or in 
combination with castration to block androgen action [5-8]. Afterwards, the 
prostate cancer cells may respond to androgen but do not require it for growth: 
these cells are androgen sensitive (AS). This leads to periods of remission from 
disease, but almost invariably, the PC recurs, by which time the PC cells have 
become androgen-independent (AI)[9,10]. In the past year, several molecular 
mechanisms for progression to hormone refractoriness have been proposed 
based on observations of experimental or clinical PC [11-14]. Five possible 
mechanisms of development of AR-independent PC have been proposed: 
 
1) The Hypersensitive pathway: more AR is produced (usually by gene 
amplification), or AR has enhanced sensitivity  to compensate for low 
levels of androgen, or more testosterone is converted to the more potent 
androgen, dihydrotestosterone (DHT), by 5α-reductase. 
2) The promiscuuos pathway: selection of mutations in the AR that confers 
broader ligand specificity (flutamide/bicalutamide itself, corticosteroid 
hormones or other similar molecules); 
3) The outlaw pathway: up-regulation of crosstalk signal transduction 
pathways that activate AR in a ligand-independent manner. For example 
receptor tyrosine kinases (RTKs) are activated, and the AR is 
phosphorylated by either the AKT (protein kinase B) or the mitogen-
activated protein kinase (MAPK) pathway, producing a ligand-
independent AR 
4)  The bypass pathway: alternative mechanisms of cell survival, for 
example activating the anti-apoptotic protein BCL2. 
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5) The lurker cell pathway: androgen-independent cancer cells that are 
present all the time in the prostate, possibly epithelial stem cells, 
might be selected by therapy. 
 
 
 
 
Figure 1. Possible mechanisms of development of androgen-indipendent PC (from [15]). 
 
 
In addition, AR can function through a suppressor element to repress its own 
expression and the expression of additional genes, including those that mediate 
androgen synthesis (Figure 2). This negative feedback loop suppresses AR 
signaling at high androgen levels but allows increased AR and androgen 
synthesis in castration-resistant prostate cancer (CRPC). Activation (or 
repression) of target genes leads to biological responses including growth, 
survival and the production of prostate-specific antigen (PSA). 
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Figure 2. Androgen action. Testosterone circulates in the blood bound to albumin 
(not shown) and sex-hormone-binding globulin (SHBG), and exchanges with free 
testosterone. Free testosterone enters prostate cells and is converted to 
dihydrotestosterone (DHT) by the enzyme 5α-reductase. Binding of DHT to the 
androgen receptor (AR) induces dissociation from heat-shock proteins (HSPs) and 
receptor phosphorylation. The AR dimerizes and can bind to androgen-response 
elements in the promoter regions of target genes. Co-activators (such as ARA70) and 
corepressors (not shown) also bind the AR complex, facilitating or preventing, 
respectively, its interaction with the general transcription apparatus (GTA). Activation 
(or repression) of target genes leads to biological responses including growth, survival 
and the production of prostate-specific antigen (PSA).  
 
Organ-confined PC is treated with surgery (radical prostectomy) or radiation 
therapy, and an increase in PSA level usually represents the first sign of 
recurrence [16]. Moreover, PC most commonly metastasizes to the bones, lymph 
nodes, and may invade rectum, bladder and lower ureters after local 
progression. The route of metastasis to bone is thought to be venous as the 
prostatic venous plexus draining the prostate connects with the vertebral veins. 
Eradication of advanced PC still represents an unsolved clinical problem, 
making the development of alternative treatment approaches desirable.  
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Ionizing radiation and prostate cancer  
Radiotherapy represents the therapeutic strategy for the treatment of an 
increasing number of tumors, included PC. Recently, various schemes of radical 
radiation therapy, based on the excellent results of phase I-II studies using the 
hypofractionation in different cancer diseases, have been developed. Thanks to 
the application of conformal/intensity-modulated techniques in combination 
with precise image-guided localization of the target, radiotherapy dose 
escalation has been shown to improve disease control. Therefore, it should be 
possible to use a larger dose per fraction without increasing the risk of serious 
late injury to the normal tissues. In the last years, studies of radiobiology 
focused to provide rationale for evaluating proteins known to play an important 
role in the control of the apoptotic pathway as potential biomarkers. Despite 
some limitations, such as time-consuming procedures, low resolution due to 
heterogeneity of proteins and post-translational modifications, proteomic 
approach could be used to study molecular biomarkers to predict and follow the 
radiotherapy response. 
Irradiation of cancer cells leads to cell death by different mechanisms as 
summarized in Figure 3 (extracted from [17]): 
 
1) DNA damage: irradiation may induce irreparable DNA damage causing 
brakes in DNA strands or leading to replicational and transcriptional 
errors. In both cases DNA damage initiates apoptosis via p53-dependent 
mechanisms;  
2) Mitochondrial damage; 
3) Oxidative stress: irradiation leads to reactive oxygen species formation, 
bringing mainly to necrosis;  
4) Plasma membrane modifications: it has been demonstrated that Cer is 
involved in cell death after irradiation via induction of apoptosis. In fact, 
several lines of evidence demonstrated, cell irradiation results in the 
activation of cell surface SMase leading to ectopic ceramide formation 
with the consequent activation of Cer-dependent-apoptosis [18]. 
 
So far, no data on the effect of ionizing radiations on the activities of PM-
associated glycosidases are available, even if some lines of evidence suggested 
that these enzymes could contribute to the formation of pro-apoptotic Cer 
under some circumstances. 
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Figure 3. Irradiation-induced cell death pathways. DNA damage (1), 
mitochondrial damage (2) and superoxide production (3) bring mainly to necrosis, 
Cer is involved in irradiation-induced apoptosis (4). 
 
 
It has been demonstrated that in human fibroblasts the over-expression of 
Neu3, which is parallel by the increase in the expression/activity of β-Gal and 
β-Gluc, causes the onset of apoptosis due to increased Cer production at the 
PM level [19,20]. Activation of glycosidases by ionizing radiations could change 
the ratio between apoptotic Cer and antiapoptotic/proliferative LacCer (Figure 
4). For example Cer produced by SM or glycolipid hydrolysis forms large Cer-
enriched membrane platforms, instrumental to the modulation of cell signaling 
processes. This could explain why some tumors are more responsive to 
irradiation than others, such as the prostate cancer, characterized by high level 
of radio resistance. For this reason big efforts are employed to develop new 
drugs, which alone or in combination with radiotherapy are able to rescue or at 
least to reduce the resistance phenomenon. 
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Figure 4. Up-regulation of cell surface-associated enzymes involved in SL-catabolism after cell 
irradiation. 
 
 
Abiraterone: new drug for PC treatment 
The development and progression of CRPC is dependent on intratumoral 
steroidogenesis, resulting in androgen synthesis and activation of the androgen 
receptor. Compared with primary prostate tumors, metastatic CRPC display 
alterations in the genes encoding steroidogenic enzymes, including the up-
regulated expression of Cytocrome P450 17α-hydroxylase/17,20-lyase 
(CYP17A1) [24]. In addition, much evidence indicates that CRPC can synthesize 
androgen from cholesterol [23]. Abiraterone acetate is a potent inhibitor of 
CYP17A1, a key enzyme in the androgen biosynthesis pathway, which is active 
in the testis and adrenal glands where it catalyzes the conversion of 
pregnenolone and progesterone into the weak androgens 
dehydroepiandrosterone and androstenedione, respectively [21,22] (Figure 5). 
Early clinical trials demonstrated that abiraterone acetate has a significant and 
sustained antitumor activity in CRPC even if its molecular mechanism that 
could be independent from the CYP17A1 inhibition is still unknown.  
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Figure 5. Mechanism of action of abiraterone acetate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  51 
Exploring the link between ceramide, abiraterone and ionizing radiation  
in prostate cancer cell death 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Aim 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  52 
Exploring the link between ceramide, abiraterone and ionizing radiation  
in prostate cancer cell death 
Prostate cancer is one of the main leading cause of cancer-related death in men 
because of the development of resistance to radiotherapy and androgen 
ablation. Interestingly, recent lines of evidence on the possible involvement of 
changes in the PM sphingolipid composition due to the activation of the PM-
associated glycohydrolases in the onset of cell death, open a new possible 
scenario also for PC. For this reason, the main aim of this thesis is to study the 
possible effect of abiraterone and ionizing radiation on the activity of the PM-
associated glycohydrolases in the production of Cer.  
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Materials 
 
Commercial chemicals were of the highest purity available, common solvents 
were distilled before use and water was doubly distilled in a glass apparatus. 
Trypsin, EDTA, Trypan blue, HEPES buffer solution, sodium pyruvate, 
aprotinine, PMSF, Glycine, reagents for cell culture and RPMI-1640 medium 
were from Sigma Chemical Co. (St Louis, MO, USA).  
Fetal bovine serum (FBS), penicillin/streptomycin and glutamine were 
purchased from EuroClone (Leeds, UK); AM-calcein, DMEM-F12 were from 
Invitrogen (Carlsbad, CA, USA).  
6-hexadecanoylamino-4-methylumbelliferone (H-MUB), 4-methylumbelliferone 
(MUB), 4-methylumbelliferyl-β-D-galactopyranoside (MUB-Gal), 4-
methylumbelliferil-β-N-acetylglucosaminide (MUG) and 4-methylumbelliferyl-β-
D-glucopyranoside (MUB-Glc) were from Glycosynth (Warrington, UK).  
6-hexadecanoylamino-4-methylumbelliferyl-phosphorylcholine (H-MUB-PC) was 
from Moscerdam Substrates (Oegstgeest, Netherland). High-performance silica 
gel thin-layer plates (HPTLC Kieselgel 60) were from Merck GmbH (Milan, Italy). 
The preparation of isotopically labeled [1-3H]sphingosine (specific radioactivity, 
2.2 Ci/mmole) has been described in detail [25].  
Abiraterone acetate was from Janssen-Cilag International. 
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METHODS 
 
Cell Cultures 
LNCaP, PC3 and DU145 prostate cancer cells were cultured and propagated in 
RPMI-1640. Medium were supplemented with 10% FCS (heat-inactivated), 1% 
glutamine, 1% penicillin/streptomycin, 1% sodium pyruvate and 1% HEPES. 
The cells were cultivated as monolayer in a humidified atmosphere at 37°C and 
5% CO2. 
 
Abiraterone treatment 
After a pivotal study aimed to establish the cytostatic but non cytotoxic 
concentration of the drug, the androgen-sensitive LNCaP cells were subjected to 
a single treatment with 10 μM abiraterone while the androgen-insensitive PC3 
and DU145 cells with 25 μM abiraterone. When the different cell lines were 
subjected to the combined treatment with abiraterone and ionizing radiation, 
cells were pre-treated with the drug for 24 hours before irradiation.  
 
Irradiation of cells 
The most widely used technique for mathematically modeling the effect of 
radiation on cancer cell survival, is linear quadratic (LQ) formalism. The core 
formula involved is an expression which correlate the probability of survival, S, 
of a population of mammalian cells following exposure to an individual 
radiation dose, d, as follows: 
S = exp[-αD-βD2] 
where α and β are tumor- or normal tissue-specific parameters. Rearrangement 
of the equation to account for the total impact of n individual fractions of 
radiation exposure yields another common expression for the biologically 
effective dose (BED):  
BED = nd(1+/α/β) 
The units of BED are Gray (Gy), the standard unit of radiation dose. The BED is 
a convenient metric for comparing the relative impact of a given schedule of 
radiation dose on a given tumor or tissue, as long as the α/β ratio is known or 
closely estimated. I irradiated the cell lines with 6 Mev photons (direct field) 
with a linear accelerator, at a single dose of 9 Gy. 
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Determination of cell viability  
At the end of the enzyme assays and at different times after irradiation and 
pharmacological treatment, cell viability was assessed by calcein staining and 
by Trypan blue exclusion test [26]. For the calcein staining, cells were washed 
with PBS, the plate was then put on ice and 200 µl of a calcein-AM solution 
(6.25 µg/ml in PBS) were added to each well. Cells were incubated for 15 
minutes at 37°C, 5% CO2. Calcein-AM was then removed and 100 µl of PBS and 
50 µl of 1% Triton X-100 were added to each well. Plate was stirred at RT for 15 
minutes and then the fluorescence was detected by a microplate reader (Victor, 
Perkin-Elmer). 
The number of living and dead cells after treatment with different abiraterone 
concentrations, has been determined by counting cells after Trypan blue 
staining, as previously described [27].  
 
Plasma Membrane (PM) associated glycohydrolase assays 
We recently described a simple method that allows to measure the activity of 
several glycohydrolases associated with the PMs in living cells. This method is 
based on the observation that the fluorigenic substrates commonly used for the 
in vitro assay of glycohydrolase activities are not taken up by living cells [26]. In 
fact, under the appropriate experimental conditions, we did not observe any 
fluorescence associated with the cells. Moreover, the artificial substrates were 
not subjected to spontaneous, non-enzymatic hydrolysis nor hydrolyzed by 
secreted enzymes. Thus, their hydrolysis under these experimental conditions is 
due exclusively to the PM-associated enzymatic activities [20,26]. PM associated 
β-Galactosidase (β-Gal), conduritol B epoxide (CBE)-sensitive β-Glucosidase 
GBA1, β-Glucosidase GBA2, β-Hexosaminidase (β-Hex) and SMase activities 
were determined in control or differently treated living cells plated in 96-well 
microplate at different density (depending on the cell lines and on the 
treatment), by a high throughput assay (HTA). For GBA1 and GBA2 assays, 
cells were pre-incubated for 30 minutes at room temperature with 5 nM AMP-
dNM (adamantane-pentyl-dNM; N-(5-adamantane-1-yl-methoxy-pentyl) 
deoxynojirimycin) [28] and 1 mM CBE (Sigma) in DMEM-F12, respectively. β-
Gal, β-Hex and β-Glc activities were assayed using the artificial substrates 
MUB-Gal, MUG and MUB-Glc solubilized in DMEM-F12 without phenol red at 
pH 6 at the final concentrations of 250 µM, 2 mM and 6 mM respectively. 
SMase activity was assayed using the artificial substrates H-MUB-PC 
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solubilized in the same DMEM-F12 reported for the other enzymes at the final 
concentration of 100 µM. At different times (from 2 to 6 hours) aliquots of the 
medium were analyzed by fluorimetry in a microplate reader (MUB: λex: 355 nm 
/λem: 460nm ; H-MUB: λex:405 nm /λem:460nm ) after adding 15 volumes of 
0.25 M glycine (containing 0,3% Triton X-100 for SMase assay), pH 10.7. 
Standards free MUB and H-MUB were used to establish the calibration curves 
in order to quantify the substrates hydrolysis.  
 
Enzymatic activities in total cell lysates 
The enzymatic activities of β-Galactosidase, β-Glucosidase GBA1 and GBA2, β-
Hexosaminidase and sialidase Neu3 in the total cell lysates were determined 
using fluorigenic substrates as previously described [26] with some 
modifications. Briefly, cells were washed twice with PBS, harvested, and 
resuspended in water in the presence of a protease inhibitor. Aliquots of cell 
homogenates were transferred to a 96-well microplate and were performed with 
three-fold in replicate. MUB substrates were solubilized in McIlvaine buffer at 
the same final concentrations and the same pH values used for the in vivo 
assay. The reaction mixtures were incubated at 37°C with gentle shaking. The 
developed fluorescence was detected at various times by a Victor microplate 
reader (Perkin Elmer) after transferring 10 μl of the reaction mixtures to a 96 
well microplate and adding 190 μl of 0.25 M glycine, pH 10.7.  
 
Cell treatments with tritiated lipids 
Treatment of cell cultures with [1-3H]sphingosine. [1-3H]sphingosine was 
administered to pharmacologically treated, 9 Gy irradiated and control cells in 
order to metabolically label all SLs as previously described [29]. [1-
3H]sphingosine dissolved in methanol was transferred into a sterile glass tube, 
and dried under a nitrogen stream; the residue was then solubilized in an 
appropriate volume of pre-warmed (37°C) cell medium to obtain the desired final 
concentration (3x10-9 M). After a 2 hours incubation (pulse), the medium was 
removed, cells were washed and incubated up to 72 hr (chase) with medium not 
containing the radioactive precursor. After chase, cells were collected and 
radioactive lipids were analyzed as described below. 
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Preparation of SL-enriched membrane domains by sucrose gradient centrifugation  
After incubation (pulse) with [1-3H]sphingosine and 72 hr (chase) with the 
different treatments, cells were collected in PBS (containing 0.4 mM Na3VO4).  
After centrifugation at 270xg for 10 minutes, cell pellet was lysed in the 1-1.5 ml 
lysis buffer (1% Triton X-100, 10 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM 
EDTA, 1 mM Na3VO4, 1 mM PMSF and 10 μM/ml aprotinin) at 4°C for 20 
minutes. After Dounce homogenization (11 strokes), each cell lysate was 
centrifuged at 1300xg for 5 minutes to remove nuclei and cellular debris, and 
the Post Nuclear Supernatant (PNS) was removed and transferred in a new 
tubes. 
The PNS fraction was mixed with an equal volume of 85% of sucrose (w/v) in 10 
mM Tris Buffer HCl pH 7.5, 150 mM NaCl, 5 mM EDTA and 1 mM Na3VO4, 
placed at the bottom of a discontinuous sucrose concentration gradient (30-5%) 
in the same buffer, and centrifuged 17 hr at 200,000xg at 4°C. After 
ultracentrifugation, eleven fraction were collected starting from the top of the 
tube. The light-scattering band, corresponding to the DRM fraction, was located 
at the interface between 5% and 30% sucrose and corresponding to fraction 5 or 
6. The entire procedure was performed in ice immersion. After that, the fractions 
were dialyzed , lyophilized and subjected to lipid extraction and SL analysis. 
 
Radioactive lipid analyses 
Cells were lyophilized and subjected to lipid extraction and SL analyses. Total 
lipids from lyophilized cells were extracted with chloroform/methanol/water 
20:10:1 by vol, followed by chloroform/methanol 2:1 by vol. The total lipid 
extracts were subjected to a two-phase partitioning by adding 20% water to the 
lipid extract; the total lipid extract, the aqueous and organic phases were 
analyzed by HPTLC. [3H]SLs of total extracts and organic phases were separated 
using the solvent system chloroform-methanol-water 110:40:6 by vol, and those 
of aqueous phases with chloroform-methanol-0.2% aqueous CaCl2, 50:42:11 by 
vol. For the specific determination of Cer content, radioactive lipids of the 
organic phases were separated using the solvent system hexane-chloroform-
acetone-acetic acid 20:70:20:2 by vol. [3H]SLs were identified by referring to the 
position of standards in the chromatogram and quantified by radioimaging after 
48 hours of acquisition (β-Imager 2000, Biospace, Paris, France).  
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Statistics 
All the experiments have been performed threefold in replicate and repeated 
three times. Data are presented as the mean values ± standard deviations and 
were tested for significance employing ONE or Two way ANOVA with Bonferroni 
post-test analysis, as specified in figure legends. The level of significance was 
set at p<0.05.  
 
Other analytical methods 
The radioactivity associated with lipid extracts was determined by liquid 
scintillation counting. The protein assays were carried out using the DC Protein 
Assay kit (Biorad). 
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Effect of abiraterone on prostate cancer cell viability 
As previously described, abiraterone is a new potential drug for prostate cancer 
treatment; this drug inhibits the androgen biosynthesis by potently blocking the 
cytochrome P450 c17, the key  enzyme in testosterone synthesis. This drug is 
also able to down regulate AR expression, and to inhibit its nuclear 
translocation, resulting in a further block of androgen-receptor signalling 
pathway. In addition, recent lines of evidence suggest other molecular 
mechanism of action of abiraterone, even if their clarification needs to be 
investigated. For this reason, I first tested the efficacy of this drug on both the 
androgen-sensitive prostate cancer cell lines  LNCaP, and the androgen-
insensitive PC3 and DU145 cells. 
In figure 6 is reported the effect of different concentrations of abiraterone 
(ranging from 0.1 to 50 μM) on LNCaP cells viability. As shown, the decreased 
number of living cells is followed by a strong increase in death cells in a time-
and dose-dependent manner. 
 
 
 
Figure 6. Effect of different concentrations of abiraterone on LNCaP cell viability. The number of living 
and death cells were evaluated by Trypan Blue exclusion test. The tested concentrations were: 0.1 μM ( ), 1 
μM ( ), 10 μM ( ), 25 μM ( ) and 50 μM ( ) respect to control cells (  ). Each value is the mean 
of three independent experiments performed in triplicate.  
 
These results indicate that abiraterone exerts an important cytotoxic effect also 
at low concentration showing a cytostatic effect at 10 μM.  
In the same experimental conditions I evaluated the effect of abiraterone on the 
androgen-insensitive PC3 and DU145 cells. Surprisingly, as shown in Figure 7 
and 8, I obtained very similar results also in these cell lines. As expected, the 
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androgen-insensitive cells are more resistant with respect to the androgen-
sensitive LNCaP cells, showing a cytostatic effect at 25 μΜ. 
 
 
Figure 7. Effect of different concentrations of abiraterone on PC3 cell viability. The number of living 
and death cells were evaluated by Trypan Blue exclusion test. The tested concentrations were: 10 μM ( ), 25 
μM ( ), 50 μM ( ) and 100 μM ( ) respect to control cells (  ). Each value is the mean of three 
independent experiments performed in triplicate.  
 
 
 
 
Figure 8. Effect of different concentration of abiraterone on DU145 cell viability. The number of the 
living and death cells were evaluated with Trypan Blue exclusion test. The testing concentrations were: 10 μM  
( ), 25 μM ( ), 50 μM ( ) and 100 μM ( ) respect to the control cells (  ).  Each value is the 
mean of three independent experiments performed in triplicate.  
 
These results indicate that abiraterone treatment causes cell growth arrest and 
death independently by the androgen pathway.  
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Effect of abiraterone and ionizing radiation treatments on prostate cancer 
cell viability 
Prostate cancer cell lines LNCaP, PC3 and DU145 are characterized by high 
level of radio-resistance; for this reason  I wondered if abiraterone could 
sensitize these cells to ionizing radiation. To this purpose, after 24 hours of pre-
treatment with abiraterone, cells were irradiated with 9 Gy and cell viability was 
evaluated at different time points. 
In Figure 9 is shown the effect of the single treatment with 10 μM abiraterone, 
and that one of ionizing radiation (9Gy) or the effect of the combined  treatment 
on LNCaP cell viability. These results indicate that the single treatment 
produces a cytostatic effect in LNCaP cells, while the combined treatment 
causes a strong increase in the number of death cells compared to each single 
treatment. 
 
 
 
 
 
Figure 9. Effect of single treatment with abiraterone or ionizing radiation and of their combined 
treatment on LNCaP cell viability. The treatment with abiraterone always started 24 hours before the 
irradiation and all the results are expressed as hours after the cell irradiation. The number of living and death 
cells were evaluated by Trypan Blue exclusion test. Each value is the mean of three independent experiments 
performed in triplicate.  
( ) Ctrl cells; ( ) 10μM abiraterone; ( ) 9Gy Ray and ( ) 10μM abiraterone + 9Gy Ray. 
 
 
I then evaluated the effect of the same treatments on both PC3 and DU145 
cells: as shown in Figure 10, I obtained very similar results, especially after the 
combined treatment with 25 μM abiraterone and 9 Gy ionizing radiation. 
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Indeed, in both experiments, after 72 hours of combined treatment, almost 90% 
reduction in cell proliferation is observed. 
 
 
 
Figure 10. Effect of single treatment with abiraterone or ionizing radiation and of their combined 
treatment on the viability of androgen-insensitive cell lines. The treatment with abiraterone always started 
24 hours before the irradiation and all the results are expressed as hours after the cell irradiation. The number 
of living cells was evaluated by Calcein staining. Each value is the mean of three independent experiments 
performed in triplicate.  
( ) Ctrl cells; ( ) 25μM abiraterone; ( ) 9Gy Ray and ( ) 25μM abiraterone + 9Gy Ray. 
 
 
These results indicate that abiraterone sensitizes prostate cancer cells to 
ionizing radiation independently from the androgen pathway. To investigate the 
possible molecular mechanism I focused the study on the possible involvement 
of the ectopic ceramide production triggered directly at the cell plasma 
membrane level. In fact, Aureli et al recently reported the first detailed 
information on the activation of several cell surface glycohydrolases in healthy 
and pathological cells subjected to ionizing radiation: this event is followed by 
the production of PM ceramide and the onset of apoptotic cell death [41]. On the 
basis of these findings  I  evaluated the activity of different glycohydrolases, 
both lysosomal and plasma-membrane associated, at different time-points after 
each single or combined treatment.  
To this regard, all prostate cancer cell lines were treated with abiraterone alone 
or ionizing radiation and with the combined treatment; then, at different time-
points cells were subjected to the evaluation of the cell surface associated 
glycohydrolases activity, in particular GBA1, GBA2, β-Galactosidase and β-
Hexosaminidase. Interestingly, as reported in Tables 1-12 the different 
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treatments cause a time dependent increase of the activity of these enzymes in 
comparison to untreated cells. In particular, in androgen-sensitive LNCaP cells 
treated with abiraterone alone or in combination with ionizing radiation, the 
activity of the PM-associated GBA1 increases after 48 hr reaching the highest 
value after 72 hr. The effects of yhe single treatment with ionizing radiation is 
different: indeed, in Figure 11, is shown a peak and through trend.  
Similar results were obtained by the analysis of GBA2, β-Galactosidase and β-
Hexosaminidase activities. In particular, all cell treatments resulted in 
increased  activity of GBA2, is i (from 2 to 2.8  fold  compared tocontrol cells) 
(Figure 12). Conversely, the activity of β-Galactosidase and β-Hexosaminidase 
shows the highest peak only when cells are subjected to the combined 
treatment with abiraterone and ionizing radiation (Figure 14). I also evaluated 
the SMase activity but no difference between treated and   control cells are 
observed (not shown data), thus suggesting that Cer does not derive from 
sphingomyeline breakdown, as previously described by Kolesnick et al. [18]. 
Collectively , these results indicate that in LNCaP cells all cell treatments cause 
an effect on the activity of plasma-membrane associated glycohydrolases. 
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Figure 11. Cell surface associated β-Glucosidase GBA1 activity in androgen-sensitive LNCaP cells 
treated with 10 μM abiraterone, 9 Gy ionizing radiation and the combined treatment. The activity was 
determined in living cells treated or not for 2 (  ), 24 (  ), 48 (  ) and 72 (  ) hours from irradiation. 
The data are the average of three experiments performed in triplicate for each cell treatment, expressed as 
percentage relative to the value of control cells (red line). Two Way ANOVA followed by Bonferroni post-tests 
#p<0.05 versus control cells, @ p<0.05 vs different treatments, *p<0.05 vs different times for the same 
treatment. 
 
 
 
 
Plasma membrane associated GBA1 
(pmoles/106 cells/hr) 
 Type of treatment 
Time after cell irradiation 
2hr 24hr 48hr 72hr 
Ctrl 3463 ± 193 3109 ± 127 4504 ± 263 3054 ± 314 
10 μM Abi 2662 ± 163 2813 ± 363 2268 ± 235 2126 ± 134 
9 Gy Ray 2055 ± 115 2695 ± 92 2500 ± 315 2443 ± 322 
10 μM Abi + 9 Gy Ray 2726 ± 157 5470 ± 481 5958 ± 336 9715 ± 388 
 
 
Table 1. GBA1 activity determined in LNCaP cells treated with 10 μM abiraterone, 9 Gy ionizing 
radiation and the combined treatment. The activity was determined in living LNCaP cells treated or not 
(Ctrl) for 2, 24, 48 and 72 hours from irradiation. Each value is the mean of three independent experiments 
performed in three-fold replicate ± SD. The data are expressed as picomoles per million cells per hours. 
# @ * # @ * 
# @ * 
# @ * 
# @ * 
# @ * # @  
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Figure 12. Cell surface associated β-Glucosidase GBA2 activity in androgen-sensitive LNCaP cells 
treated with 10 μM abiraterone, 9 Gy ionizing radiation and the combined treatment. The activity was 
determined in living cells treated or not for 2 (  ), 24 (  ), 48 (  ) and 72 (  ) hours from irradiation. 
The data are the average of three experiments performed in triplicate for each cell treatment, expressed as 
percentage relative to the value of control cells (red line). Two Way ANOVA followed by Bonferroni post-tests 
#p<0.05 versus control cells, @ p<0.05 vs different treatments, *p<0.05 vs different times for the same 
treatment. 
 
 
 
 
Plasma membrane associated GBA2 
(pmoles/106 cells/hr) 
 Type of treatment 
Time after cell irradiation 
2hr 24hr 48hr 72hr 
Ctrl 1184 ± 146 1131 ± 183 1613 ± 151 1403 ± 183 
10 μM Abi 793 ± 51 1092 ± 140 702 ± 49 697 ± 62 
9 Gy Ray 434 ± 75 378 ± 71 497 ± 28 832 ± 157 
10 μM Abi + 9 Gy Ray 804 ± 76 2688 ± 67 1139 ± 158 2091 ± 153 
 
 
Table 2. GBA2 activity determined in LNCaP cells treated with 10 μM abiraterone, 9 Gy ionizing 
radiation and the combined treatment. The activity was determined in living LNCaP cells treated or not 
(Ctrl) for 2, 24, 48 and 72 hours from irradiation. Each value is the mean of three independent experiments 
performed in three-fold replicate ± SD. The data are expressed as picomoles per million of cell per hours. 
# @ * 
# @ * 
# @ * 
# @ * 
#      # 
# @ *  
#      # 
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Figure 13. Cell surface associated β-Galactosidase activity in androgen-sensitive LNCaP cells treated 
with 10 μM abiraterone, 9 Gy ionizing radiation and the combined treatment. The activity was 
determined in living cells treated or not for 2 (  ), 24 (  ), 48 (  ) and 72 (  ) hours from irradiation. 
The data are the average of three experiments performed in triplicate for each cell treatment, expressed as 
percentage relative to the value ofcontrol cells (red line). Two Way ANOVA followed by Bonferroni post-tests 
#p<0.05 versus control cells, @ p<0.05 vs different treatments, *p<0.05 vs different times for the same 
treatment. 
 
 
 
 
Plasma membrane associated β-Galactosidase 
(pmoles/106 cells/hr) 
 Type of treatment 
Time after cell irradiation 
2hr 24hr 48hr 72hr 
Ctrl 620 ± 101 755 ± 49 820 ± 167.5 425 ± 63.6 
10 μM Abi 375 ± 37 368 ± 33 357 ± 52.9 304 ± 23.3 
9 Gy Ray 345 ± 23 513 ± 58 539 ± 41.2 990 ± 330.0 
10 μM Abi + 9 Gy Ray 447 ± 8 813 ± 65 2892 ± 324 2411 ± 124 
 
 
Table 3. β-Galactosidase activity determined in LNCaP cells treated with 10 μM abiraterone, 9 Gy 
ionizing radiation and the combined treatment. The activity was determined in living LNCaP cells treated 
or not for 2, 24, 48 and 72 hours from irradiation. Each value is the mean of three independent experiments 
performed three-fold in replicate ± SD. The data are expressed as picomoles per million cells per hours. 
# @ * 
# @ * 
# @ * 
# @ * 
#           #  
 
 # @ * 
#           
#  
 
 # @ * 
#           #  
 
 # @ * 
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Figure 14. Cell surface associated β-Hexosaminidase activity in androgen-sensitive LNCaP cells 
treated with 10 μM abiraterone, 9 Gy ionizing radiation and the combined treatment. The activity was 
determined in living cells treated or not for 2 (  ), 24 (  ), 48 ( ) and 72 (  ) hours from e irradiation. 
The data are the average of three experiments performed in triplicate for each cell treatment, expressed as 
percentage relative to the value of control cells (red line). Two Way ANOVA followed by Bonferroni post-tests 
#p<0.05 versus control cells, @ p<0.05 vs different treatments, *p<0.05 vs different times for the same 
treatment. 
 
 
 
 
Plasma membrane associated β-Hexosaminidase 
(pmoles/106 cells/hr) 
 Type of treatment 
Time after cell irradiation 
2hr 24hr 48hr 72hr 
Ctrl 10340 ± 902 18816 ± 1114 10676 ± 574 16482 ± 1698 
10 μM Abi 13442 ± 593 18588 ± 1078 18130 ± 1346 24179 ± 652 
9 Gy Ray 7781 ± 771 14317 ± 1325 14441 ± 1306 25673 ± 3732 
10 μM Abi + 9 Gy Ray 10521 ± 385 26407 ± 1051 50810 ± 2097 196616 ± 1882 
 
 
Table 4. β-Hexosaminidase activity determined in LNCaP cells treated with 10 μM abiraterone, 9 Gy 
ionizing radiation and the combined treatment. The activity was determined in living LNCaP cells treated 
or not (Ctrl) for 2, 24, 48 and 72 hours from irradiation. Each value is the mean of three independent 
experiments performed in three-fold replicate ± SD. The data are expressed as picomoles per million cells per 
hours. 
 
# @ * 
# @ * # @ * 
# @ * 
# @ * # @ * 
# # 
#@   #@ 
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Different results were obtained in androgen-insensitive PC3 cells. In fact, in 
these cells the single treatment with 25 μΜ abiraterone does nott induce any 
variation in the PM-associated activity of GBA1, GBA2, β-Galactosidase and β-
Hexosaminidase. Conversely, as shown in Figure 15, in PC3 cells the single 
treatment  with ionizing radiation induces an higher increase in the activity of 
the PM-associated GBA1 after 2 hr followed by a reduction at 24 hr and 
increase again at 72 hr. In addition, the combined treatment induces an 
increase in the GBA1 activity starting at 48 hr and reaching the highest value 
after 72 hours.  
The same trend is also found for the activity of GBA2 (Figure 16), β-
Galactosidase (Figure 17) and β-Hexosaminidase (Figure 18), where the single 
treatment with ionizing radiation determines an higher increase after 2 hr and 
the combined treatment causes the highest increase after 72 hours from the 
irradiation. All these data suggest that in androgen-insensitive PC3 cells, 
ionizing radiation treatment cause firstly a change on plasma-membrane 
glycohydrolases activities which is notably more evident when the cells are 
subjected to the combined treatment. 
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Figure 15. Cell surface associated β-Glucosidase GBA1 activity in androgen-insensitive PC3 cells 
treated with 25 μM abiraterone, 9 Gy ionizing radiation and the combined treatment. The activity was 
determined in living cells treated or not for 2 (  ), 24 ( ), 48 (  ) and 72 (  ) hours from irradiation. 
The data are the average of three experiments performed in triplicate for each cell treatment, expressed as 
percentage relative to the valueof control cells (red line). Two Way ANOVA followed by Bonferroni post-tests 
#p<0.05 versus control cells, @ p<0.05 vs different treatments, *p<0.05 vs different times for the same 
treatment. 
 
 
 
Plasma membrane associated GBA1 
(pmoles/106 cells/hr) 
 Type of treatment 
Time after cell irradiation 
2hr 24hr 48hr 72hr 
Ctrl 390 ± 58.4 224 ± 11.7 910 ± 0.4 361 ± 5.7 
25 μM Abi 381 ± 17.7 184 ± 22.4 375 ± 24.4 205 ± 4.8 
9 Gy Ray 612 ± 46.7 627 ± 52.4 748 ± 37.3 732 ± 58.1 
25 μM Abi + 9 Gy Ray 834 ± 31.6 539 ± 28.4 1428 ± 158.5 2832 ± 113.1 
 
Table 5. GBA1 activity determined in PC3 cells treated with 25 μM abiraterone, 9 Gy ionizing radiation 
and the combined treatment. The activity was determined in living PC3 cells treated or not (Ctrl) for 2, 24, 
48 and 72 hours from irradiation. Each value is the mean of three independent experiments performed in 
three-fold replicate ± SD. The data are expressed as picomoles per million cells per hours. 
 
# @ * 
# @ * 
# @ * 
# # 
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Figure 16. Cell surface associated β-Glucosidase GBA2 activity in androgen-insensitive PC3 cells 
treated with 25 μM abiraterone, 9 Gy ionizing radiation and the combined treatment. The activity was 
determined in living PC3 cells treated or not for 2 (  ), 24 ( ), 48 (  ) and 72 (  ) hours from 
irradiation. The data are the average of three experiments performed in triplicate for each cell treatment, 
expressed as percentage relative to the value of control cells (red line). Two Way ANOVA followed by 
Bonferroni post-tests #p<0.05 versus control cells, @ p<0.05 vs different treatments, *p<0.05 vs different 
times for the same treatment. 
 
 
Plasma membrane associated GBA2 
(pmoles/106 cells/hr) 
 Type of treatment 
Time after cell irradiation 
2hr 24hr 48hr 72hr 
Ctrl 118 ± 8.4 83 ± 7.2 231 ± 35.1 112 ± 31.1 
25 μM Abi 206 ± 10.7 174 ± 5.5 136 ± 8.7 291 ± 19.6 
9 Gy Ray 282 ± 31.3 316 ± 7.6 348 ± 7.7 744 ± 48.1 
25 μM Abi + 9 Gy Ray 685 ± 33.1 675 ± 55.9 849 ± 20.2 2057 ± 127.3 
 
Table 6. GBA2 activity determined in PC3 cells treated with 25 μM abiraterone, 9 Gy ionizing 
radiation and the combined treatment. The activity was determined in living PC3 cells treated or not (Ctrl) 
for 2, 24, 48 and 72 hours from irradiation. Each value is the mean of three independent experiments 
performed in three-fold replicate ± SD. The data are expressed as picomoles per million cells per hours. 
 
 
 
 
 
# @ * 
# @ * 
# @ * 
# @ * 
#  #       # 
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Figure 17. Cell surface associated β-Galactosidase activity in androgen-insensitive PC3 cells treated 
with 25 μM abiraterone, 9 Gy ionizing radiation and the combined treatment. The activity was 
determined in PC3 living cells treated or not for 2 (  ), 24 ( ), 48 (  ) and 72 (  ) hours from 
irradiation. The data are the average of three experiments performed in triplicate for each cell treatment, 
expressed as percentage relative to the value of control cells (red line). Two Way ANOVA followed by 
Bonferroni post-tests #p<0.05 versus control cells, @ p<0.05 vs different treatments, *p<0.05 vs different 
times for the same treatment. 
 
Plasma membrane associated β-Galactosidase 
(pmoles/106 cells/hr) 
 Type of treatment 
Time after cell irradiation 
2hr 24hr 48hr 72hr 
Ctrl 429 ± 70.9 353 ± 29.4 820 ± 167.5 425 ± 63.6 
25 μM Abi 211 ± 36.2 224 ± 31.1 357 ± 52.9 304 ± 23.3 
9 Gy Ray 245 ± 20.0 275 ± 15.1 539 ± 41.2 990 ± 330.0 
25 μM Abi + 9 Gy Ray 591 ± 41.1 739 ± 44.8 1151 ± 58.3 3135 ± 310.0 
 
Table 7. β-Galactosidase activity determined in PC3 cells treated with 25 μM abiraterone, 9 Gy 
ionizing radiation and the combined treatment. The activity was determined in living PC3 cells treated or 
not (Ctrl) for 2, 24, 48 and 72 hours from irradiation. Each value is the mean of three independent experiments 
performed in three-fold replicate ± SD. The data are expressed as picomoles per million cells per hours. 
 
# @ * 
# @ * 
# @  
# @  
# @  
# @  
# @ * 
#*  
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Figure 18. Cell surface associated β-Hexosaminidase activity in androgen-insensitive PC3 cells treated 
with 25 μM abiraterone, 9 Gy ionizing radiation and the combined treatment. The activity was 
determined in PC3 living cells treated or not for 2 (  ), 24 (  ), 48 (  ) and 72 (  ) hours from 
irradiation. The data are averages of three experiments performed in triplicate for each cell treatment, expressed 
as percentage relative to the value of control cells (red line). Two Way ANOVA followed by Bonferroni post-
tests #p<0.05 versus control cells, @ p<0.05 vs different treatments, *p<0.05 vs different times for the same 
treatment. 
 
Plasma membrane associated β-Hexosaminidase 
(pmoles/106 cells/hr) 
 Type of treatment 
Time after cell irradiation 
2hr 24hr 48hr 72hr 
Ctrl 23963 ± 1124 22553 ± 1320 61908 ± 10076 29148 ± 921 
25 μM Abi 13037 ± 2013 13560 ± 1398 21983 ± 1695 21781 ± 593 
9 Gy Ray 18669 ± 869 25430 ± 1780 27758 ± 806 35001 ± 1244 
25 μM Abi + 9 Gy Ray 29961 ± 1493 21644 ± 1363 41265 ± 2429 119413 ± 8403 
 
Table 8. β-Hexosaminidase activity determined in PC3 cells treated with 25 μM abiraterone, 9 Gy 
ionizing radiation and the combined treatment. The activity was determined in living PC3 cells treated or 
not (Ctrl)for 2, 24, 48 and 72 hours from irradiation. Each value is the mean of three independent experiments 
performed in three-fold replicate ± SD. The data are expressed as picomoles per million cells per hours. 
 
 
 
 
 
 
# @ * 
# @ * 
# * #      #            # 
# @ 
# @ * 
# @ 
  75 
Exploring the link between ceramide, abiraterone and ionizing radiation  
in prostate cancer cell death 
The same experiments were performed in androgen-insensitive DU145 cells. As 
shown in Figure 19, the activity of PM-associated GBA1 increases 2.5 times after 2 
hours from cell irradiation. Also in this case, the major effect is exerted by the 
combined treatment that induces 2 and 4 fold increase in the GBA1 activity after 
48 and 72 hours respectively. Differently, the activity of the PM-associated GBA2 
(Figure 20), increases 3 fold after 48 and 72 hours from the single treatment with 
abiraterone, while no changes are observed after irradiation. Finally, after 48 and 
72 hours from the combined treatment, GBA2 activity increases respectively 6 and 
7 fold respect to control cells. 
As shown in Figure 21, the activity of β-Galactosidase increases after 48 and 72 
hours after all the different cell treatments reaching the highest activity after the 
combined treatment. Similar results were obtained also for β-Hexosaminidase 
activity as shown in Figure 22. 
All these results indicate that in androgen-insensitive DU145 cells, all the 
treatment cause an increase in plasma-membrane associated glycohydrolases 
activities; in particular, the combined treatment with abiraterone and ionizing 
radiation is most effective. 
In summary all the cell lines tested show that the combined treatment induces a 
major cytotoxic effect which is accompanied by the highest increase in the PM-
associated hydrolases activity.  
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Figure 19. Cell surface associated β-Glucosidase GBA1 activity in androgen-insensitive DU145 cells 
treated with 25 μM abiraterone, 9 Gy ionizing radiation and the combined treatment. The activity was 
determined in living cells treated or not for 2 (  ), 24 (  ), 48 (  ) and 72 (  ) hours from irradiation. 
The data are the average of three experiments performed in triplicate for each cell treatment, expressed as 
percentage relative to the value of control cells (red line). Two Way ANOVA followed by Bonferroni post-tests 
#p<0.05 versus control cells, @ p<0.05 vs different treatments, *p<0.05 vs different times for the same 
treatment. 
 
 
 
 
 
Plasma membrane associated GBA1 
(pmoles/106 cells/hr) 
 Type of treatment 
Time after cell irradiation 
2hr 24hr 48hr 72hr 
Ctrl 227 ± 26.2 194 ± 40.3 540 ± 40.8 548 ± 22.0 
25 μM Abi 138 ± 9.8 127 ± 18.1 175 ± 22.6 114 ± 24.5 
9 Gy Ray 189 ± 21.3 247 ± 48.5 258 ± 9.7 355 ± 34.3 
25 μM Abi + 9 Gy Ray 287 ± 13.8 342 ± 47.2 356 ± 18.7 1102 ± 5.7 
 
Table 9. GBA1 activity determined in DU145 cells treated with 25 μM abiraterone, 9 Gy ionizing 
radiation and the combined treatment. The activity was determined in living DU145 cells treated or not 
(Ctrl) for 2, 24, 48 and 72 hours from irradiation. Each value is the mean of three independent experiments 
performed in three-fold replicate ± SD. The data are expressed as picomoles per million cells per hours. 
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Figure 20. Cell surface associated β-Glucosidase GBA2 activity in androgen-insensitive DU145 cells 
treated with 25 μM abiraterone, 9 Gy ionizing radiation and the combined treatment. The activity was 
determined in living cells treated or not for 2 (  ), 24 (  ), 48 (  ) and 72 (  ) hours from irradiation. 
The data are the average of three experiments performed in triplicate for each cell treatment, expressed as 
percentage relative to the value of control cells (red line). Two Way ANOVA followed by Bonferroni post-tests 
#p<0.05 versus control cells, @ p<0.05 vs different treatments, *p<0.05 vs different times for the same 
treatment. 
 
 
Plasma membrane associated GBA2 
(pmoles/106 cells/hr) 
 Type of treatment 
Time after cell irradiation 
2hr 24hr 48hr 72hr 
Ctrl 105 ± 25.6 94 ± 12.2 145 ± 57.8 128 ± 58.6 
25 μM Abi 70 ± 9.4 52 ± 6.2 89 ± 2.1 113 ± 28.0 
9 Gy Ray 79 ± 5 243 ± 23.8 88 ± 4.2 452 ± 30.8 
25 μM Abi + 9 Gy Ray 168 ± 27.3 492 ± 9.0 201 ± 9.2 1108 ± 123.3 
 
Table 10. GBA2 activity determined in DU145 cells treated with 25 μM abiraterone, 9 Gy ionizing 
radiation and the combined treatment. The activity was determined in living DU145 cells treated or not 
(Ctrl) for 2, 24, 48 and 72 hours from irradiation. Each value is the mean of three independent experiments 
performed in three-fold replicate ± SD. The data are expressed as picomoles per million cells per hours. 
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Figure 21. Cell surface associated β-Galactosidase activity in androgen-insensitive DU145 cells treated 
with 25 μM abiraterone, 9 Gy ionizing radiation and the combined treatment. The activity was 
determined in living cells treated or not for 2 (  ), 24 (  ), 48 (  ) and 72 (  ) hours from the 
irradiation. The data are the average of three experiments performed in triplicate for each cell treatment, 
expressed as percentage relative to the value of control cells (red line). Two Way ANOVA followed by 
Bonferroni post-tests #p<0.05 versus control cells, @ p<0.05 vs different treatments, *p<0.05 vs different 
times for the same treatment. 
 
 
 
Plasma membrane associated β-Galactosidase 
(pmoles/106 cells/hr) 
 Type of treatment 
Time after cell irradiation 
2hr 24hr 48hr 72hr 
Ctrl 471 ± 27.9 378 ± 5.9 459 ± 34.3 353 ± 15.6 
25 μM Abi 209 ± 11.5 135 ± 4.3 284 ± 22.7 184 ± 7.8 
9 Gy Ray 219 ± 20.4 243 ± 45.8 429 ± 12.9 734 ± 72.4 
25 μM Abi + 9 Gy Ray 329 ± 20.1 559 ± 32.1 534 ± 44.5 1604 ± 111.7 
 
Table 11. β-Galactosidase activity determined in DU145 cells treated with 25 μM abiraterone, 9 Gy 
ionizing radiation and the combined treatment. The activity was determined in living DU145 cells treated 
or not (Ctrl) for 2, 24, 48 and 72 hours from irradiation. Each value is the mean of three independent 
experiments performed in three-fold replicate ± SD. The data are expressed as picomoles per million cells per 
hours. 
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Figure 22. Cell surface associated β-Hexosaminidase activity in androgen-insensitive DU145 cells 
treated with 25 μM abiraterone, 9 Gy ionizing radiation and the combined treatment. The activity was 
determined in living cells treated or not for 2 (  ), 24 (  ), 48 (  ) and 72 (  ) hours from irradiation. 
The data are the average of three experiments performed in triplicate for each cell treatment, expressed as 
percentage relative to the value of control cells (red line). Two Way ANOVA followed by Bonferroni post-tests 
#p<0.05 versus control cells, @ p<0.05 vs different treatments, *p<0.05 vs different times for the same 
treatment. 
 
 
 
Plasma membrane associated β-Hexosaminidase 
(pmoles/106 cells/hr) 
 Type of treatment 
Time after cell irradiation 
2hr 24hr 48hr 72hr 
Ctrl 20721 ± 1842 25197 ± 1046 30814 ± 4881 33617 ± 557 
25 μM Abi 8907 ± 76 9992 ± 405 12892 ± 524 14580 ± 725 
9 Gy Ray 8234 ± 405 15731 ± 426 18413 ± 1109 36212 ± 980 
25 μM Abi + 9 Gy Ray 8303 ± 191 18842 ± 2014 17420 ± 1362 66995 ± 6750 
 
Table 12. β-Hexosaminidase activity determined in DU145 cells treated with 25 μM abiraterone, 9 Gy 
ionizing radiation and the combined treatment. The activity was determined in living DU145 cells treated 
or not (Ctrl) for 2, 24, 48 and 72 hours from irradiation. Each value is the mean of three independent 
experiments performed in three-fold replicate ± SD. The data are expressed as picomoles per million cells per 
hours. 
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Effect of abiraterone and ionizing radiation treatments on glycohydrolase 
activities associated with the total cell lysate in androgen sensitive and 
insensitive-prostate cancer cell lines  
Most of  Glycohydrolases, whose activity is can be measured at the plasma 
membrane level, are mainly  intracellular enzymes. For this reason, the activity 
of GBA1, non-lysosomal β-Glucosidase GBA2, β-Galactosidase and β-
Hexosaminidase were also measured in the total cell lysate of the different PC 
cell lines subjected to single treatment with abiraterone or ionizing radiation 
and both.  
In LNCaP cells the treatment with abiraterone induces a mild increase only of 
GBA2 and β-Galactosidase activity (figures 24-25). Instead, the combined 
treatment induces an increase on the activity of GBA1, β-Galactosidase and β-
Hexosaminidase (Figures 23-25-26). 
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Figure 23. Activity of CBE-sensitive β-Glucosidase GBA1 in androgen-sensitive LNCaP cells treated 
with 10 μM abiraterone, 9 Gy ionizing radiation and the combined treatment. The activity was 
determined in total cell lysate of LNCaP cells treated or not for 2 (  ), 24 (  ) and 48 (  ) hours from 
irradiation, and was evaluated in the presence of the specific inhibitor of GBA2, the AMP-dNM. The data are 
the average of three experiments performed in triplicate for each cell treatment, expressed as percentage 
relative to the value of control cells (red line). Two Way ANOVA followed by Bonferroni post-tests #p<0.05 
versus control cells, @ p<0.05 vs different treatments, *p<0.05 vs different times for the same treatment. 
 
 
 
Activity of GBA1 in total cell lysate 
(pmoles/mg protein/hr) 
 Type of treatment 
Time after cell irradiation 
2hr 24hr 48hr 
Ctrl 8068 ± 267 8892 ± 241 10281 ± 151 
10 μM Abi 5500 ± 536 10107 ± 460 11364 ± 511 
9 Gy Ray 5874 ± 426 9348 ± 739 10706 ± 1008 
10 μM Abi + 9 Gy Ray 5150 ± 186 10914 ± 897 9762 ± 536 
 
 
Table 13. GBA1 activity determined in LNCaP cells treated with 10 μM abiraterone, 9 Gy ionizing 
radiation and the combined treatment. The activity was determined in cell lysate of LNCaP cells treated or 
not (Ctrl) for 2, 24 and 48 hours from irradiation. Each value is the mean of three independent experiments 
performed in three-fold replicate ± SD. The data are expressed as picomoles per milligram cell proteins per 
hours. 
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Figure 24. Activity of AMP-dNM-sensitive β-Glucosidase GBA2 in androgen-sensitive LNCaP cells 
treated with 10 μM abiraterone, 9 Gy ionizing radiation and the combined treatment. The activity was 
determined in total cell lysate of LNCaP cells treated or not for 2 (  ), 24 (  ) and 48 (  ) hours from 
irradiation, and was evaluated in the presence of the specific inhibitor of GBA1, CBE. The data are the average 
of three experiments performed in triplicate for each cell treatment, expressed as percentage relative to the 
value of control cells (red line). Two Way ANOVA followed by Bonferroni post-tests #p<0.05 versus control 
cells, @ p<0.05 vs different treatments, *p<0.05 vs different times for the same treatment. 
 
 
 
 
 
Activity of GBA2 in total cell lysate 
(pmoles/mg protein/hr) 
 Type of treatment 
Time after cell irradiation 
2hr 24hr 48hr 
Ctrl 3836 ± 185 3899 ± 529 3381 ± 412 
10 μM Abi 2885 ± 184 4170 ± 294 4172 ± 123.4 
9 Gy Ray 3026 ± 70 2765 ± 123 2731 ± 227 
10 μM Abi + 9 Gy Ray 2561 ± 72 3619 ± 479 3036 ± 360 
 
 
 
Table 14. GBA2 activity determined in LNCaP cells treated with 10 μM abiraterone, 9 Gy ionizing 
radiation and the combined treatment. The activity was determined in cell lysate of LNCaP cells treated or 
not (Ctrl) for 2, 24 and 48 hours from irradiation. Each value is the mean of three independent experiments 
performed in three-fold replicate ± SD. The data are expressed as picomoles per milligram cell proteins per 
hours. 
 
# @ * 
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Figure 25. Activity of β-Galactosidase in androgen-sensitive LNCaP cells treated with 10 μM 
abiraterone, 9 Gy ionizing radiation and the combined treatment. The activity was determined in total cell 
lysate of LNCaP cells treated or not for 2 (   ), 24 (  ) and 48 (  ) hours from irradiation. The data are 
the average of three experiments performed in triplicate for each cell treatment, expressed as percentage 
relative to the value of control cells (red line). Two Way ANOVA followed by Bonferroni post-tests #p<0.05 
versus control cells, @ p<0.05 vs different treatments, *p<0.05 vs different times for the same treatment. 
 
 
 
Activity of β-Galactosidase in total cell lysate 
(nmoles/mg protein/hr) 
 Type of treatment 
Time after cell irradiation 
2hr 24hr 48hr 
Ctrl 68.8 ± 2.2 97.1 ± 5.6 88.7 ± 3.8 
10 μM Abi 59.4 ± 0.9 108.2 ± 7.1 108.6 ± 2.1 
9 Gy Ray 60.4 ± 2.7 99.3 ± 5.1 111.9 ± 1.4 
10 μM Abi + 9 Gy Ray 54.1 ± 0.9 111 ± 3.7 116.8 ± 4.9 
 
Table 15. β-Galactosidase activity determined in LNCaP cells treated with 10 μM abiraterone, 9 Gy 
ionizing radiation and the combined treatment. The activity was determined in cell lysate of LNCaP cells 
treated or not (Ctrl) for 2, 24 and 48 hours from irradiation. Each value is the mean of three independent 
experiments performed in three-fold replicate ± SD. The data are expressed as nanomoles per milligram cell 
proteins per hours. 
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Figure 26. Activity of β-Hexosaminidase in androgen-sensitive LNCaP cells treated with 10 μM 
abiraterone, 9 Gy ionizing radiation and the combined treatment. The activity was determined in total cell 
lysate of LNCaP cells treated or not for 2 (  ), 24 (  ) and 48 (  ) hours from irradiation. The data are 
the average of three experiments performed in triplicate for each cell treatment, expressed as percentage 
relative to the value of control cells (red line). Two Way ANOVA followed by Bonferroni post-tests #p<0.05 
versus control cells, @ p<0.05 vs different treatments, *p<0.05 vs different times for the same treatment. 
 
 
 
 
 
Activity of β-Hexosaminidase in total cell lysate 
(nmoles/mg protein/hr) 
 Type of treatment 
Time after cell irradiation 
2hr 24hr 48hr 
Ctrl 1802 ± 7.3 2312 ± 77.8 2190 ± 114.4 
10 μM Abi 1462 ± 0.8 2378 ± 110.7 2369 ± 47.0 
9 Gy Ray 1499 ± 9.5 2269 ± 191.3 2513 ± 82.7 
10 μM Abi + 9 Gy Ray 1334 ± 10.3 2375 ± 222.9 2463 ± 110 
 
 
Table 16. β-Hexosaminidase activity determined in LNCaP cells treated with 10 μM abiraterone, 9 Gy 
ionizing radiation and the combined treatment. The activity was determined in cell lysate of LNCaP cells 
treated or not (Ctrl) for 2, 24 and 48 hours from irradiation. Each value is the mean of three independent 
experiments performed in three-fold replicate ± SD. The data are expressed as nanomoles per milligram cell 
proteins per hours. 
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In androgen-insensitive PC3 cells the activities of GBA1 (Figure 27), GBA2 
(Figure 28) and β-Galactosidase (Figures 29) increase after all the cell 
treatment, especially after the single treatment with abiraterone and after the 
combined one. Differently, the activity of the β-Hexosaminidase does not show 
any change (Figure 30). 
This trend is also maintained by GBA1 (Figure 31), β-Galactosidase (Figure 33) 
and β-Hexosaminidase (Figure 34) activities in DU145 cells, while the activity of 
GBA2 increases after 48 hours with the single treatment of abiraterone or in 
combination with irradiation (Figure 32). 
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Figure 27. Activity of CBE-sensitive β-Glucosidase GBA1 in androgen-insensitive PC3 cells treated 
with 25 μM abiraterone, 9 Gy ionizing radiation and the combined treatment. The activity was 
determined in total cell lysate of LNCaP cells treated or not for 2 (  ) and 48 (  ) hours from the 
irradiation. The data are the averageof three experiments performed in triplicate for each cell treatment, 
expressed as percentage relative to the value of control cells (red line). Two Way ANOVA followed by 
Bonferroni post-tests #p<0.05 versus control cells, @ p<0.05 vs different treatments, *p<0.05 vs different 
times for the same treatment. 
 
 
 
 
 
 
Activity of GBA1 in total cell lysate 
(pmoles/mg protein/hr) 
 Type of treatment 
Time after cell irradiation 
2hr 48hr 
Ctrl 568 ± 33 545 ± 69 
25 μM Abi 848 ± 75 893 ± 47 
9 Gy Ray 622 ± 36 736 ± 17 
25 μM Abi + 9 Gy Ray 881 ± 30 642 ± 23 
 
 
 
Table 17. GBA1 activity determined in PC3 cells treated with 25 μM abiraterone, 9 Gy ionizing 
radiation and the combined treatment. The activity was determined in cell lysate of PC3 cells treated or not 
(Ctrl) for 2 and 48 hours from irradiation. Each value is the mean of three independent experiments performed 
in three-fold replicate ± SD. The data are expressed as picomoles per milligram cell proteins per hours 
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Figure 28. Activity of AMP-dNM-sensitive β-Glucosidase GBA2 in androgen-insensitive PC3 cells 
treated with 25 μM abiraterone, 9 Gy ionizing radiation and the combined treatment. The activity was 
determined in total cell lysate of PC3 cells treated or not for 2 (  ) and 48 (  ) hours from irradiation. The 
data are the average of three experiments performed in triplicate for each cell treatment, expressed as 
percentage relative to the value of control cells (red line). Two Way ANOVA followed by Bonferroni post-tests 
#p<0.05 versus control cells, @ p<0.05 vs different treatments, *p<0.05 vs different times for the same 
treatment. 
 
 
 
 
 
 
 
Activity of GBA2 in total cell lysate 
(pmoles/mg protein/hr) 
Type of treatment 
Time after cell irradiation 
2hr 48hr 
Ctrl 388 ± 40 462 ± 12 
25 μM Abi 682 ± 64 730 ± 11 
9 Gy Ray 471 ± 14 591 ± 14 
25 μM Abi + 9 Gy Ray 731 ± 34 506 ± 30 
 
 
Table 18. GBA2 activity determined in PC3 cells treated with 25 μM abiraterone, 9 Gy ionizing 
radiation and the combined treatment. The activity was determined in cell lysate of PC3 cells treated or not 
(Ctrl) for 2 and 48 hours from irradiation. Each value is the mean of three independent experiments performed 
in three-fold replicate ± SD. The data are expressed as picomoles per milligram cell proteins per hours. 
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Figure 29. Activity of β-Galactosidase in androgen-insensitive PC3 cells treated with 25 μM 
abiraterone, 9 Gy ionizing radiation and the combined treatment. The activity was determined in total cell 
lysate of PC3 cells treated or not for 2 (  ) and 48 (  ) hours from irradiation. The data are averages of 
three experiments performed in triplicate for each cell treatment, expressed as percentage relative to the value 
of control cells (red line). Two Way ANOVA followed by Bonferroni post-tests #p<0.05 versus control cells, 
@ p<0.05 vs different treatments, *p<0.05 vs different times for the same treatment. 
 
 
 
 
 
Activity of β-Galactosidase in total cell lysate 
(nmoles/mg protein/hr) 
Type of treatment 
Time after cell irradiation 
2hr 48hr 
Ctrl 33.4 ±0.6 27.5 ± 1.1 
25 μM Abi 41.9 ± 2.1 34.5 ± 1.9 
9 Gy Ray 38.0 ± 1.0 36.9 ± 0.4 
25 μM Abi + 9 Gy Ray 48.7 ± 2.6 32.4 ± 1.3 
 
Table 19. β-Galactosidase activity determined in PC3 cells treated with 25 μM abiraterone, 9 Gy 
ionizing radiation and the combined treatment. The activity was determined in cell lysate of PC3 cells 
treated or not (Ctrl) for 2 and 48 hours from irradiation. Each value is the mean of three independent 
experiments performed in three-fold replicate ± SD. The data are expressed as nanomoles per milligram cell 
proteins per hours. 
 
 
 
 
 
 
 
# @ * 
# @ * 
# @      #@ 
  89 
Exploring the link between ceramide, abiraterone and ionizing radiation  
in prostate cancer cell death 
 
 
 
 
Figure 30. Activity of β-Hexosaminidase in androgen-insensitive PC3 cells treated with 25 μM 
abiraterone, 9 Gy ionizing radiation and the combined treatment. The activity was determined in total cell 
lysate of PC3 cells treated or not for 2 (  ) and 48 (  ) hours from irradiation. The data are the average of 
three experiments performed in triplicate for each cell treatment, expressed as percentage relative to the value 
of control cells (red line). Two Way ANOVA followed by Bonferroni post-tests #p<0.05 versus control cells. 
 
 
 
 
Activity of β-Hexosaminidase in total cell 
lysate 
(nmoles/mg protein/hr) 
Type of treatment 
Time after cell irradiation 
2hr 48hr 
Ctrl 550 ± 3.6 476 ± 2.3 
25 μM Abi 603 ± 16.6 446 ± 5.1 
9 Gy Ray 580 ± 11.9 556 ± 21.3 
25 μM Abi + 9 Gy Ray 640 ± 22.6 350 ± 23.5 
 
 
 
Table 20. β-Hexosaminidase activity determined in PC3 cells treated with 25 μM abiraterone, 9 Gy 
ionizing radiation and the combined treatment. The activity was determined in cell lysate of PC3 cells 
treated or not (Ctrl) for 2 and 48 hours from irradiation. Each value is the mean of three independent 
experiments performed in three-fold replicate ± SD. The data are expressed as nanomoles per milligram cell 
proteins per hours. 
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Figure 31. GBA1 activity determined in androgen-insensitive DU145 cells treated with 25 μM 
abiraterone, 9 Gy ionizing radiation and the combined treatment. The activity was determined in cell 
lysate of DU145 cells treated or not for 2 (  ) to 48 (  ) hours from irradiation. The data are expressed as 
enzyme activity respect to the control cells (red line).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 21. GBA1 activity determined in androgen-insensitive DU145 cells treated with 25 μM 
abiraterone, 9 Gy ionizing radiation and the combined treatment.  
The activity was determined in cell lysate of DU145 cells treated or not (Ctrl) for 2 to 48 hours from the 
irradiation. Each value is the mean of three independent experiments performed in three-fold replicate ± SD. 
The data are expressed as picomoles per milligram cell proteins per hours. 
 
 
 
Activity of GBA1 in total cell lysate 
(pmoles/mg protein/hr) 
 Type of treatment 
Time after cell irradiation 
2hr 48hr 
Ctrl 938 ± 79 751 ± 29 
25 μM Abi 902 ± 90  815 ± 31 
9 Gy Ray 653 ± 14 825 ± 40 
25 μM Abi + 9 Gy Ray 1039 ± 34 800 ± 38 
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Figure 32. Activity of AMP-dNM-sensitive β-Glucosidase GBA2 in androgen-insensitive DU145 cells 
treated with 25 μM abiraterone, 9 Gy ionizing radiation and the combined treatment. The activity was 
determined in total cell lysate of DU145 cells treated or not for 2 (  ) and 48 (  ) hours from the 
irradiation. The data are the average of three experiments performed in triplicate for each cell treatment, 
expressed as percentage relative to the value of control cells (red line). Two Way ANOVA followed by 
Bonferroni post-tests #p<0.05 versus control cells, @ p<0.05 vs different treatments, *p<0.05 vs different 
times for the same treatment. 
 
 
Activity of GBA2 in total cell lysate 
(pmoles/mg protein/hr) 
Type of treatment 
Time after cell irradiation 
2hr 48hr 
Ctrl 449 ± 38 389 ± 14 
25 μM Abi 480 ± 81 570 ± 39 
9 Gy Ray 192 ± 11 364 ± 29 
25 μM Abi + 9 Gy Ray 581 ± 17 593 ± 26 
 
Table 22. GBA2 activity determined in DU145 cells treated with 25 μM abiraterone, 9 Gy ionizing 
radiation and the combined treatment. The activity was determined in cell lysate of DU145 cells treated or 
not (Ctrl) for 2 and 48 hours from irradiation. Each value is the mean of three independent experiments 
performed in three-fold replicate ± SD. The data are expressed as picomoles per milligram cell proteins per 
hours. 
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Figure 33. Activity of β-Galactosidase in androgen-insensitive DU145 cells treated with 25 μM 
abiraterone, 9 Gy ionizing radiation and the combined treatment. The activity was determined in total cell 
lysate of DU145 cells treated or not for 2 (  ) and 48 (  ) hours from the irradiation. The data are the 
average of three experiments performed in triplicate for each cell treatment, expressed as percentage relative to 
the value of control cells (red line).  
 
 
Activity of β-Galactosidase in total cell lysate 
(nmoles/mg protein/hr) 
Type of treatment 
Time after cell irradiation 
2hr 48hr 
Ctrl 58 ± 3.1 31 ± 1.9 
25 μM Abi 66 ± 3.5 33 ± 1.8 
9 Gy Ray 51 ± 1.8 34 ± 1.4 
25 μM Abi + 9 Gy Ray 62 ± 1.5 25 ± 1.4 
 
Table 23. β-Galactosidase activity determined in DU145 cells treated with 25 μM abiraterone, 9 Gy 
ionizing radiation and the combined treatment. The activity was determined in cell lysate of DU145 cells 
treated or not (Ctrl) for 2 and 48 hours from irradiation. Each value is the mean of three independent 
experiments performed in three-fold replicate ± SD. The data are expressed as nanomoles per milligram cell 
proteins per hours. 
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Figure 34. Activity of β-Hexosaminidase in androgen-insensitive DU145 cells treated with 25 μM 
abiraterone, 9 Gy ionizing radiation and the combined treatment. The activity was determined in total cell 
lysate of DU145 cells treated or not for 2 (  ) and 48 (  ) hours from irradiation. The data are the average 
of three experiments performed in triplicate for each cell treatment, expressed as percentage relative to the 
value of control cells (red line).. 
 
 
 
Activity of β-Hexosaminidase in total cell 
lysate 
(nmoles/mg protein/hr) 
Type of treatment 
Time after cell irradiation 
2hr 48hr 
Ctrl 837 ± 88  506 ± 15 
25 μM Abi 609 ± 43 476 ± 22 
9 Gy Ray 658 ± 67 537 ± 23 
25 μM Abi + 9 Gy Ray 762 ± 88 363 ± 26 
 
Table 24. β-Hexosaminidase activity determined in DU145 cells treated with 25 μM abiraterone, 9 Gy 
ionizing radiation and the combined treatment. The activity was determined in cell lysate of DU145 cells 
treated or not (Ctrl) for 2 and 48 hours from irradiation. Each value is the mean of three independent 
experiments performed in three-fold replicate ± SD. The data are expressed as nanomoles per milligram cell 
proteins per hours. 
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Effect of different treatments on ceramide production 
All the results obtained on the enzymatic activities indicate that the most 
significant variation occurs at the PM level. It is of common knowledge that the 
increased activity of these enzyme in response to different stimuli (such as 
chemo- and radiotherapy), could rapidly activate the hydrolysis of complex 
glycosphingolipids, leading to the ectopic production of ceramide and the onset 
of cell apoptosis. To this purpose, the analysis of sphingolipid pattern and 
composition after the different cell treatments has been performed:, cells were 
first treated with abiraterone and/or irradiation, and then SLs were 
metabolically radiolabeled at the steady state with [1-3H]sphingosine. As shown 
in Figure 35 and Table 25, in LNCaP cells all the different treatments induce an 
increase in ceramide content. In particular, the treatment with 10 μM 
abiraterone, 9 Gy ionizing radiation and the combined one, induces a 2, 2.5 and 
3.3 fold increase in ceramide level  respectively.  
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Figure 35. HPTLC separation of  total radioactive lipids extracted from LNCaP cells subjected to 
different treatments. Extraction was performed 72 hr from cell irradiation. Total lipid extract was separated 
on HPTLC silica gel 100 plates using the solvent system chloroform-methanol-water 110:40:6 by volume. 700 
dpm were applied in each line and after separation HPTLC were  submitted to 3 days counting by  digital radio-
imaging.  
 
 
 
 
 
Table 25. Radioactivity quantification of sphingolipids after HPTLC separation as reported in Figure 
35 (24 hr) data are expressed as percentage relative of single species respect to total sphingolipid amount. Data 
represent the mean ± SD, n = 2 independent experiments, 3 replicates for each experiment.  
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Comparable results were observed also for the androgen-insensitive PC3 and 
DU145 cell lines (Figure 36-37, Table 26-27): in particular, after the single 
treatment with 25 μM abiraterone and the combined one in PC3 cells, Cer rose 
up respectively 1.7 and 2.2 fold respect to control cells, while the single 
treatment with ionizing radiation does not cause a significant increase in Cer 
level. Moreover, in DU145 cells Cer rose up respectively 1.7, 1.8 and 2.1 fold 
respect to control cells.  
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Figure 36. HPTLC separation of total radioactive lipids extracted from PC3 cells subjected to the 
different treatments. Extraction was performed 72 hr from the cell irradiation. Total extract was separated on 
HPTLC silica gel 100 plates using the solvent system chloroform-methanol-water 110:40:6 by volume. 700 dpm 
were applied in each line and after separation, HPTLC were submitted to 3 day counting by digital radio-
imaging.  
 
 
Table 26. Radioactivity quantification of sphingolipids separated by HPTLC as reported in Figure 36 
(24 hr); data are expressed as percentage relative of single species respect to the total sphingolipid amount. 
Data represent the mean ± SD, n = 2 independent experiments, 3 replicates for each experiment.  
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Figure 37.  HPTLC separation of total radioactive lipids extracted from DU145 cells subjected to 
different treatments. Extraction was performed 72 hr from the cell irradiation. Total extract was separated on 
HPTLC silica gel 100 plates using the solvent system chloroform-methanol-water 110:40:6 by volume. 700 dpm 
were applied in each line and after separation, HPTLC were submitted to 3 day counting by digital radio-
imaging.  
 
 
Table 27. Radioactivity quantification of sphingolipids separated by HPTLC as reported in Figure 37 
(24 hr); data are expressed as percentage relative of single species respect to the total sphingolipid amount. 
Data represent the mean ± SD, n = 2 independent experiments, 3 replicates for each experiment.  
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All these results suggest that in PC cells the different treatments cause 
significant changes in the cell sphingolipid content and pattern; this should be 
followed by changes in the plasma membrane cell structure. It is of common 
knowledge that sphingolipids segregate within cholesterol leading to the 
creation of membrane domains called Sphingolipid Enriched Membrane 
Domains (SEMD). These domains are also enriched in selected proteins involved 
in the control of signal transduction. Indeed, it has been demonstrated that the 
SEMD are involved in the regulation of several cellular processes including cell 
death. For this reason, in order to evaluate the possible molecular mechanism 
involved in the cell death I purified SEMD by using  a method based on the 
separation on a sucrose gradient, followed by ultracentrifugation in order to 
obtain detergent insoluble low-density membrane fractions. The SEMD were 
prepared for all the prostate cancer cell lines subjected to the treatments 
described before: only vehicle, abiraterone, ionizing radiation and both the 
treatments. After feeding experiments with radioactive sphingosine (in 
conditions to radiolabel cell sphingolipids  at the steady state), cells were 
harvested, lysed and centrifuged to obtain the Post Nuclear Supernatant (PNS). 
PNS were loaded on a discontinuous sucrose gradient, ultracentrifuged and 
eleven fractions (#) were collected from the top of each tube. The radioactivity 
associated with each fraction was determinate by liquid scintillation counting, 
and as shown in Figures 38-40-42, cell-radioactivity, mainly due to SLs, was 
largely associated with fractions 5-6, corresponding to the low density fractions 
(DRM) that are resistant to detergent solubilization. Moreover, some 
radioactivity was also associated with fractions 10-11, corresponding to the 
high density fractions (HD fraction) that contain membrane solubilized by 
detergent and the higher quantity of cell proteins. Interestingly, the DRM 
fractions prepared from all the cell lines tested, show an increase in ceramide 
level after  all the cell treatments respect to control cells. 
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Distribution of the radioactive sphingolipids among the different gradient fractions  
in androgen-sensitive LNCaP cells 
 
Figure 38. LNCaP gradient fractions analysis. Distribution of total radioactivity in sucrose density fractions 
from control (Ctrl) and treated cells. The data as percentage relative of single fraction radioactivity with respect 
to total radioactivity. 
 
Figure 39. HPTLC separation of radioactive total lipid extract obtained from DRM fractions prepared 
from control and treated LNCaP cells. A total of 800 dpm of lipid extract were applied on a 4 mm line. 
HPTLC was run in the solvent system chloroform-methanol-water, 110:40:6 by volume. Digital 
autoradiography was performed with a Biospace β-imager instrument for 48 hours. 
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Distribution of the radioactive sphingolipids in the different sucrose gradient fractions  
in androgen-insensitive PC3 cells 
 
Figure 40. PC3 gradient fraction analysis. Distribution of total radioactivity in sucrose density fractions 
from control (Ctrl) and treated cells. The data as percentage relative of single fraction radioactivity with respect 
to  total radioactivity. 
 
Figure 41. HPTLC separation of radioactive total lipid extract obtained from DRM fractions prepared 
from control and treated PC3 cells. A total of 800 dpm of lipid extract were applied on a 4 mm line. HPTLC 
was run in the solvent system chloroform-methanol-water, 110:40:6 by volume. Digital autoradiography was 
performed with a Biospace β-imager instrument for 48 hours. 
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Distribution of the radioactive sphingolipids in  different sucrose gradient fractions  
in androgen-insensitive DU145 cells 
 
Figure 42. DU145 gradient fraction analysis. Distribution of total radioactivity in sucrose density fractions 
from control (Ctrl) and treated cells. The data as percentage relative of single fraction radioactivity with respect 
to the total amount of radioactivity. 
 
Figure 43. HPTLC separation of radioactive total lipid extract obtained from DRM fractions prepared 
from control and treated DU145 cells. A total of 800 dpm of lipid extract were applied on a 4 mm line. 
HPTLC was run in the solvent system chloroform-methanol-water, 110:40:6 by volume. Digital 
autoradiography was performed with a Biospace β-imager instrument for 48 hours. 
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SL glycohydrolases have been known from long time as lysosomal catabolic 
enzymes necessary to remove the hydrophilic head from SLs to obtain ceramide. 
Cer is then hydrolyzed by ceramidase to sphingosine that can be recycled or 
completely catabolyzed, outside of lysosomes, to water and carbon dioxide [30].  
Recently, more specific information suggests the presence of some SL 
hydrolases at the plasma membrane [31]. The availability of a simple 
methodology able to selectively detect the enzyme activities associated with PM 
on living cells, without the interference of the enzymatic lysosomal activities, 
allowed to better understand the behavior of these enzymes [26].  
Some of them are localized at plasma membrane as a consequence of fusion 
processes between lysosomes and PM, whereas other ones are resident PM-
enzymes with  structures and properties different from the lysosomal enzymes, 
such as the β-glucocerebrosidase GBA2, sialidase Neu3 and probably the 
neutral SMase [31]. The action of these enzymes, which modifies the SL 
structure has been considered a system able to change the PM organization and 
properties, mainly related to cell signaling processes [32]. An increase in the 
activity of PM SMase is claimed to be responsible for the formation of large Cer-
rich platforms necessary for the cell signaling [33]. Activation of SMase by TNF-
α leads to the Cer dependent phosphorylation cascade resulting in cell 
apoptosis [34]. The activation of the plasma membrane SMase after ionizing 
radio-treatment used on radiotherapy is well known to have a central role in cell 
death and tumor reduction, through cell apoptosis caused by an increase of PM 
Cer [36,36]. Previously, it has been shown that in human fibroblasts an 
increased expression of sialidase Neu3 was associated with a rise of β-
Glucosidase and β-Galactosidase activity, followed by a further increase on PM 
ceramide content leading to apoptotic cell death [19].  
In this thesis I show some results on the plasma-membrane glycohydrolase 
activity. obtained in different PC cell lines after the treatment with the anti-
androgen drug abiraterone,  ionizing radiation and their combined treatment. 
The data demonstrate that in all the cells tested, the PM-associated GBA1, 
GBA2, β-Galactosidase and β-Hexosaminidase activities increase after the cell 
treatments. Conversely, the activity of sphingomyelinase remain constant [35]. 
The reason leading to the increase in the PM associated glycohydrolase 
activities has not yet been clarified; it is probably due to an increase expression, 
an augmented PM translocation or conformational changes of the enzyme 
structure. This latter hypothesis has already been postulated for 
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sphingomyelinase by Haimovitz-Friedman et al. [36] and, considering the 
irradiation energy, it is not surprising that it could modify the enzyme 
conformation and activity. Moreover, the data show that changes of plasma 
membrane enzyme activities occur after only 2 hours from cell irradiation, but 
at this time point is difficult to hypothesize if the increased activity is due to an 
increased expression. In addition, the rise of the glycohydrolases activity is 
followed by an increase of ceramide content in the sphingolipid enriched 
membrane fractions (DRM). The increase of PM Cer in cells subjected to ionizing 
radiations has been shown to participate to the onset of cell death [40].  
These data suggest the involvement of glycohydrolases in plasma membrane 
Cer production; at this site, Cer may be involved in the molecular mechanisms 
leading to cell apoptosis. This could enrich the knowledge on the apoptotic 
pathway induced by ionizing radiation (summarized in Figure 44). The 
possibility that PM glycohydrolases could participate to the induction of 
apoptosis in tumor cells opens the way to design and use drugs able to 
modulate their activity increasing the irradiation-induced cell death. Moreover, 
the action of the cell surface associated glycohydrolases are not only restricted 
to GSLs metabolism but also to other cell surface glycoconjugates. Their 
modifications, which occur during cell irradiation need to be further studied in 
the future. 
 
 
Figure 44. Simplified scheme of the effects of ionizing radiation on cells in culture. 
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BLADDER CANCER 
 
Epidemiology and incidence 
Bladder cancer (BC) is the most common malignancy form of the genitourinary 
tract. It’s estimated more than 350 000 diagnosed cases each year, with an 
incidence two fold higher in Caucasians [1] and three fold higher in men than 
women, which, however, show a more advanced stage of disease and lower 
chance of survival [2]. Bladder cancer is usually diagnosed in elderly 
individuals, with an average age of 69 years for men and 71 for women [3].  
 
Risk factors 
Several risk factors have been investigated in order to assess a correlation with 
the occurrence of BC: smoking is the most important risk factor for bladder 
cancer. Smokers are at least 3 times as likely to get bladder cancer as 
nonsmokers. Smoking causes about half of the bladder cancers in both men 
and women. When smokers inhale, some of the carcinogens (cancer-causing 
chemicals) in tobacco smoke are absorbed from the lungs and get into the 
blood. From the blood, they are filtered by the kidneys and concentrated in the 
urine. These chemicals in urine can damage the cells that line the inside of the 
bladder, which increases the chance of cancer developing [4,5]. Workers in 
industries that use certain organic chemicals also may be at risk for bladder 
cancer if exposure is not limited by good workplace safety practices. The 
industries carrying highest risks include the makers of rubber, leather, 
textiles, and paint products as well as printing companies. Other workers with 
an increased risk of developing bladder cancer include painters, machinists, 
printers, hairdressers (likely because of heavy exposure to hair dyes), and 
truck drivers (likely because of exposure to diesel fumes) [6]. In addition, 
chemotherapy and ionizing radiation therapy has been reported increase the 
risk of bladder cancer: cyclophosphamide is an alkylating agent used in the 
treatment of lymphomas and leukemias resulting particularly toxic to the 
lining of the bladder leading to anomalies epithelium [7]. The treatment of a 
primary tumor with ionizing radiation may lead to the development of a 
secondary tumor to bladder [8]. Urinary infections, kidney and bladder stones, 
bladder catheters left in place a long time, and other causes of chronic bladder 
irritation have been linked with bladder cancer (especially squamous cell 
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carcinoma of the bladder), but it is not clear if they actually cause bladder 
cancer. Schistosomiasis (also known as bilharziasis), an infection with a 
parasitic worm called Schistosoma hematobium that can get into the bladder, 
is also a risk factor for bladder cancer. In countries where this parasite is 
common (mainly in Africa and the Middle East), squamous cell cancers of the 
bladder are seen much more often. This is an extremely rare cause of bladder 
cancer in the United States. 
 
Classification and staging 
Bladder cancer is a very heterogeneous disease. Histologically can manifest 
as urothelial carcinoma, adenocarcinoma, squamous cell carcinoma and 
small cell carcinoma. In more than 90% of cases occur as urothelial or 
transitional cells, and 70-85% of these are defined and categorized as 
superficial non-muscle invasive bladder cancer (NMIBC) as opposed to 
muscle-invasive cancer (MIBC) which affects the deeper layers of the bladder 
tissue and muscle [9]. The grade of the tumor is a parameter that is 
considered to have prognostic information and for assessing the progression. 
The classification was proposed by the World Health Organization (WHO) 
and the International Society of Urological Pathology (ISUP) in 1973 and then 
revised in 2004 [10]. This classification provides for the presence of a low 
and a high degree of carcinoma which differ for a different incidence of the 
risk of progression and a different cell differentiation (Figure 1). 
 
  
Figure 1. WHO classification of bladder cancer. 
 
The pathologic stage of urothelial carcinoma is very important to determine 
prognosis and treatment, and the classification system that takes account of 
the staging of cancer is the TNM (tumor/node/metastasis), developed in 
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1946 by the “Union Internationale Contre le Cancer “ and subsequently revised. 
This classification allows to evaluate bladder tumors by local extension (T), 
to the interest of regional lymph nodes (N) and presence of distant 
metastasis (M) (Figure 2). 
 
 
Figure 2. TNM Classification. The TNM Classification of Malignant Tumours 
(TNM) is a cancer staging notation system that gives codes to describe the stage of a 
person's cancer, when this originates with a solid tumor: T describes the size of the 
original (primary) tumor and whether it has invaded nearby tissue, N describes nearby 
(regional) lymph nodes that are involved, M describes distant metastasis (spread of 
cancer from one part of the body to another). 
 
 
Based on the TNM system pT0, pTa, pT1 and pTis were considered non-
muscle invasive tumors and pT2, pT3 and pT4 as muscle invasive tumors 
[11]. PT0 cancer is a condition in which there is no evidence of residual 
cancer after an initial diagnosis; stadium pTa is defined as non-muscle-
invasive papillary carcinoma with no invasion of the lamina propria; pT1 
identifies the invasion of the lamina propria [10-13]. Among the superficial 
tumors are also identifies carcinoma in situ (CIS). CIS is a non-invasive 
urothelial carcinoma, consists of cytologically high grade tumour cells [14, 
15]. Finally, the stage pT2, pT3 and pT4, are muscle invasive tumors that 
identify, first, an invasion of the muscularis mucosae, and second, invasion 
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to perivesical tissue and adjacent organs, such as uterus , vagina, prostate, 
pelvic and abdominal wall [11] (Figure 3). 
 
 
Figure 3. The TNV classification can be integrated into a numerical staging as follows: Stage 0a: 
Ta, N0, M0, Stage 0is: Tis, N0, M0; Stage I: T1, N0, M0; Stage II: T2a or T2b, N0, M0; Stage III: T3a, 
T3b, or T4a, N0, M0; Stage IV; any of the following: T4b, N0, M0 any T, N1 to N3, M0 any T, any N, 
M1. 
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Clinically, 75-80% of bladder neoplasms correspond to non-muscle-invasive 
bladder cancer (NMIBC) at diagnosis. After transurethral resection of the 
tumor followed by adjuvant chemotherapy, 30 to 50% of patients recur, and 
more than 15% of those undergo progression to muscle-invasive disease [16]. 
Identification of novel potential targets to reduce recurrence and prevent 
disease progression represents a medical need for bladder cancer. Among the 
various putative novel biomarkers or targets recently described for urothelial 
carcinoma [17], the endocannabinoid system (ECS) expressed by the 
genitourinary organs has recently gained particular attention. The ECS 
components such as CB1, CB2 receptors, and the endocannabinoid-
degrading enzyme fatty acid amide hydrolase (FAAH) are present in the 
bladder at the epithelial level and play a role in regulating bladder functions 
{18-20]. As recently shown, both clinical and experimental evidence has 
indicated a possible role of the ECS in modulating cancer proliferation, 
progression and metastasis [21] in several types of neoplastic diseases, 
including, prostate and breast cancer [22,23]. Of note, little information is 
available on the possible role of ECS components in proliferation [24] and 
metastasis of human urothelial carcinoma, or on the mechanisms 
underlying progression to the muscle invasive phenotype. In this context, 
glycosphingolipids (GSL) play an important role. As previously reported GSL 
are components of the cell plasma membranes that change dramatically 
during differentiation and malignant transformation [25]. Aggressive, 
muscle-invasive bladder cancer is in fact characterized by a different 
expression of the glycolipids GM3 and Gb3 [26], suggesting that the 
metabolism of GSL plays a role in controlling bladder cancer cell invasion 
and motility [27]. Similarly, the known antiproliferative activity of 
cannabinoids in cancer models is reported to involve the activation of 
membrane-associated metabolism of sphingolipids with concomitant 
accumulation of ceramide (Cer) via de novo synthesis [28-30] and possible 
activation of the Cer/sphingosine-1-phosphate (S1P) rheostat [31]. However, 
the role of CB2 activators in bladder cancer survival and motility and the 
interplay with GSL pathways still remains poorly characterized.   
The present study is aimed to investigate the expression and activity of CB2 
receptor in human bladder cancer in relation to molecular signals mediated 
by plasma membrane GSL. I have identified a molecular pathway, partly 
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based on CB2-dependent modulation of GSL, by which bladder cancer 
survival and progression is possibly mediated.  
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Materials and Methods 
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MATERIALS 
RPMI 1640 medium, trypsin-EDTA solution, MTT, protease/phosphatase 
inhibitor cocktail, and JWH015, were purchased from Sigma (Milan, IT). The 
Fetal calf serum was from Gibco (Euroclone, Milan, IT). Primary antibodies 
anti-CB1, anti-CB2 and anti-FAAH, anandamide, rimonabant, SR144528, 
oleoyl ethyl amide and Annexin V/PI detection kit were from Cayman 
Chemical (Space Import, Milan, IT).  The primary antibody anti-GAPDH and 
HRP conjugated secondary antibodies were from Santa Cruz Biotechnology. 
Primary antibodies anti-cleaved Caspase-3, Ezrin EZR, pERM were from Cell 
Signaling Technology (Danvers, MA, USA), while anti SRC/pSRC were from 
AbCam.  
The preparation of isotopically labeled of [1-3H]sphingosine (specific 
radioactivity, 2.2 Ci/mmole) has been described in detail [32].  
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METHODS 
Immunohistochemical Analysis of Human bladder cancer 
After institutional Ethical Committee approval, archival material was 
obtained from internal pathologists. Histology was carried out on surgical 
specimens of 13 consecutive patients, not subjected to neoadjuvant 
chemotherapy, with transitional, muscle-invasive bladder cancer, which 
were fixed in 4% paraformaldehyde solution in PBS, paraffin embedded, cut 
at 4 µm and mounted on slides. Sections were stained with either 
hematoxylin-eosin or for immunohistochemistry by using a LSAB+HRP Kit 
(DAKO). The specificity of CB1 and CB2 antibodies has been previously 
described [33,34]. Immunohistochemical staining’s were digitally scanned 
and analyzed by using the Aperio system with color deconvolution algorithm.  
 
Cell cultures and treatments 
Human transitional carcinoma cell lines RT112 and RT4 were originally 
purchased from ATCC. Both tumor cell lines were maintained in RPMI 1640 
medium supplemented with 10% FCS. Cells were routinely subcultured by 
0.05% trypsinization. Normal human fibroblast were cultured as previously 
reported [35]. MB49 murine bladder cancer cells were kindly provided by Dr. 
Angelica Loskog (University of Uppsala, Sweden) and routinely cultured as 
above. For cell viability assay, cells were seeded in quadruplicates in 96-well 
plates and incubated in 200 µl of complete RPMI to achieve 60% to 90% 
confluency. Cannabinoid agonists and/or antagonists were serially diluted 
(0.1-20 µM) into culture medium; cells were exposed to the compounds 
ranging from 24 to 120 hours. Cell viability was assayed by standard MTT 
incorporation. To perform metabolic labeling, cells were pulsed with 3 x 10-8 
M [1-3H]sphingosine 24 hrs after seeding in a culture dish. Two hours after, 
cells were replaced with fresh medium without [1-3H]sphingosine containing 
20 µM JWH015 and further incubated for 72 hours. Under these conditions, 
all sphingolipids (including ceramide, sphingomyelin, neutral glycolipids, 
and gangliosides) were metabolically radiolabeled at a steady state [36]. 
 
Immunoblotting analysis of protein patterns 
Cells were lysed in ice-cold RIPA buffer containing protease and phosphatase 
inhibitors.  Equivalent protein amounts were separated on SDS-PAGE gels 
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and transferred onto PVDF membrane by elettroblotting. After blocking with 
5% skim milk in TBS-T buffer, membranes were incubated ON at 4°C with 
primary antibody. After washing, 1 hour (RT) incubation with appropriate 
HRP-labeled secondary antibodies was done. Immunoblot was revealed by 
using a chemoluminescence detection kit (Life Technologies, Milan IT). 
Densitometric analysis was performed with ImageJ (Denovo software). 
 
Lipid extraction and determination 
Upon metabolic steady-state radiolabelling of cellular lipids with [1-
3H]sphingosine, the content of radioactivity associated with each lipid was 
analyzed. Radiolabeled cells were harvested in 2-ml ice-cold water and 
lyophilized. Cellular lipids were then extracted by using a 
chloroform/methanol/water solution (2:1:0.1 by vol).  The total lipid extracts 
were subjected to a two-phase partitioning and processed as previously 
described [37]. 
 
RNA isolation and RT-PCR analysis 
Total RNA was isolated from the bladder cancer cells using a TRIzol Reagent 
kit (Invitrogen, Carlsbad, CA). Complementary DNA (cDNA) was synthesized 
from total RNA by using Super ScriptTM III Reverse Transcriptase (RT; 
Invitrogen). The following primer pairs were used:  hCB2 forward 5’- 
TATGGGCATGTTCTCTGGAA-3’, reverse 5’-GAGGAGCACAGCCAACACTA-3’; 
hCB1 forward 5’-CGCTTTCCGGAGCATGTT-3’, reverse 5’-
TCCCCCATGCTGTTATCCA-3’;  β-actin forward 5’-
CGACAGGATGCAGAAGGAG-3’, reverse 5’-ACATCTGCTGGAAGGTGGA-3’. 
Thirty-five cycles were performed at 94°C for 30 sec, 57°C for 1 min and 
72°C for 1 min (see suppl. Methods for primer sequences). The PCR products 
were separated on 1.5% (w/v) agarose gel and visualized by ethidium 
bromide staining. 
 
Real-time qPCR 
One µg of total RNA was reverse-transcribed into cDNA using a High 
Capacity cDNA kit (Applied Biosystems) according to the manufacturer’s 
protocol. RT-PCR was performed on an ABI Prism 7000 system (Applied 
Biosystems, Foster City, CA, USA) and the cycling conditions used were 95°C 
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for 15 sec, 60°C for 1 min, for 40 cycles, followed by a melting point 
determination for dissociation curves. The relative amount of mRNA was 
calculated by using standard curves after normalization to the endogenous 
housekeeping genes GAPDH and HPRT1. PCR primers were designed with 
the Primer3 program to generate amplicons of 100-150 bp. The following 
primer pairs were used: GAPDH forward 5’-GGACTCATGACCACAGTCCA; 
reverse 5’- CCAGTAGAGGCAGGGATGAT; HPRT1, forward 5’- 
TGCAGACTTTGCTTTCCTTG; reverse 5’- CTGGCTTATATCCAACACTTCG; 
CB1, forward 5’- CCAGCAGACCAGGTGAACAT; reverse 5’- 
GGGTTCAGGACCATGAAACACT; CB2 , forward 5’-
CCTGTTCATTGGCAGCTTGG; reverse 5’-TCAGCAGGAAGACAGCCTTG; alpha 
1,4-galactosyltransferase (A4GALT), forward 5’- TCTGCACCCTGTTCATCATC; 
reverse 5’- CTTTCTCCTTGGGCTCTCC; ceramide synthase 2 (CERS2), 
forward 5’- TCCGACTGGGACTCTTAATC;  reverse 5’- 
TGTTGCAGGTGTTCTTCCAT; ceramide synthase 3 (CERS3), forward 5’-
GAATCAAGAGAGGCCTTCCA ;  reverse 5’-GCAATTCCAGCAACAGTGAT; 
membrane sialidase 3 (NEU3), forward 5’-CCTGAAGCCACTGATGGAA ;  
reverse 5’-TTCCTGCCTGACACAATCTG; Lactosylceramide alpha-2,3-
sialyltransferase (ST3GAL5); forward 5’-AATTGGCGCTGTTATTTGAGC;  
reverse 5’-CTGGCAAGAGTTCCAAGAGG; sphingosine kinase 1 (SPHK1), 
forward 5’-CCCCAGCAAACCGGACCGAC;  reverse 5’-
CCCCAGCAAACCGGACCGAC; sphingosine kinase 2 (SPHK2), forward 5’-
CCCCTCAGACTCAGCGGCCT;  reverse 5’-GTGGGCGAGGCAGGTTCCAC.  
  
Wound-healing/invasion assays 
Cells were plated at 90% confluence in 5% serum-DMEM. Twenty-four hours 
after seeding, the monolayers were scratched with a sterile plastic 200-μL 
micropipette tip, washed, and fed with culture medium containing the 
appropriate concentrations of DMSO or JWH015 compound. Cell-free area 
was quantified using ImageJ software (Denovo software). Three 
measurements were performed for each wound before the addition of 
agonists and, in a blinded fashion, after 24 hours of stimulation. Each 
experiment was performed in triplicate at least 3 times. Invasion assay was 
carried out in BioCoat Matrigel Invasion Chambers (BD Biosciences, Milan, 
Italy) according to the manufacturer’s protocol. 
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Plasma Membrane (PM) associated glycohydrolase assays 
We recently described a simple method, that allows to measure the activity of 
several glycohydrolases associated with the PMs of intact living cells [38]. 
This method is based on the observation that the fluorigenic substrates 
commonly used for the in vitro assay of glycohydrolase activity are not taken 
up by living cells [39]. In fact, under the appropriate experimental 
conditions, we did not observe any fluorescence associated with the cells. 
Moreover, the artificial substrates were not subjected to spontaneous, non-
enzymatic hydrolysis nor hydrolyzed in observable entity by secreted 
enzymes. Thus, their hydrolysis under these experimental conditions is due 
exclusively to the PM associated enzymatic activities [37,38]. PM associated 
β-galactosidase (β-Gal), conduritol B epoxide (CBE)-sensitive β-glucosidase 
GBA1, β-glucosidase GBA2, β-hexosaminidase (β-Hex) and SMase activities 
were determined in control or differently treated living cells plated in 96-well 
microplate at different density (depending on the cell lines and by the type of 
treatment), by a high throughput assay (HTA). For GBA1 and GBA2 assays, 
the cells were pre-incubated for 30 minutes at room temperature with 5 nM 
AMP-dNM (adamantane-pentyl-DNM; N-(5-adamantane-1-yl-methoxy-pentyl) 
deoxynojirimycin) [39] and 1 mM CBE (Sigma) in DMEM-F12, respectively. 
The β-Gal, β-Hex and β-Glc activities were assayed using the artificial 
substrates MUB-Gal, MUG and MUB-Glc solubilized in DMEM-F12 without 
phenol red at pH 6 at the final concentrations of 250 µM, 2 mM and 6 mM 
respectively. At various times, aliquots of the medium were analyzed 
fluorometrically by using a microplate reader (Victor, Perkin Elmer) with the 
addition of 20  volumes of 0.25 M glycine (Sigma), pH 10.7. The data were 
expressed as n/pmoles of converted substrate/mg cells proteins/hr. Control 
experiments were performed to exclude any activity released from lysosomes 
and/or from other intracellular sites. 
 
Enzymatic activities of cell lysates 
The enzymatic activities of β-Galactosidase, β-Glucosidase GBA1 and GBA2 
and β-Hexosaminidase associated with total cell lysates were determined 
using fluorigenic substrates as described previously [40] with some 
modifications. Briefly, cells were washed twice with PBS, harvested, and 
resuspended in water in the presence of a protease inhibitor. Aliquots of the 
cell homogenates were transferred into a 96-well microplate and enzymatic 
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assays performed with three-fold replication. MUB substrates were 
solubilized in McIlvaine buffer at the same final concentration and the same 
pH used for the in vivo assay. The reaction mixtures were incubated at 37°C 
with gentle shaking. The developed fluorescence was detected at various 
times by a Victor microplate reader (Perkin Elmer) after transferring 10 μl of 
the reaction mixtures to a microplate and adding 190 μl of 0.25 M glycine, 
pH 10.7.  
Sphingosine kinase 1 (SK1) activity was assayed as previously described 
[41]. For the analysis of sphingosine-1-phosphate (S1P) production, cells 
were pulsed with [1-3H]sphingosine for 45 min as previously described [42].  
 
Statistics 
All the experiments have been performed threefold in replicate and repeated 
three times. Data are presented as the mean values ± standard deviations 
and were tested for significance employing ONE or Two way ANOVA with 
Bonferroni post-test analysis, as specified in figure legends. The level of 
significance was set at p<0.05.  
 
Other analytical methods 
The radioactivity associated with lipid extracts was determined by liquid 
scintillation counting. The protein assays were carried out using the DC 
Protein Assay kit (Biorad). 
 126 
Bladder cancer cell growth and motility implicate cannabinoid 2 
receptor-mediated modifications of sphingolipids metabolism 
 
 
 
 
 
 
 
 
 
 
Results 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 127 
Bladder cancer cell growth and motility implicate cannabinoid 2 
receptor-mediated modifications of sphingolipids metabolism 
Expression of cannabinoid receptors in human bladder cancer 
Immuno-histochemistry on tissue slides showed specific reactivity for both 
CB1 and CB2 in normal urothelium, vascular endothelium and 
inflammatory infiltrates. Whereas immunoreactivity for CB1 appeared 
similar in healthy and neoplastic lesions, signal for CB2 was observed to be 
increased in tumor tissue. Particularly, by comparing the malignant 
urothelium and stroma (Figure 1, panel A-B, arrowheads) to the adjacent 
normal peritumoral tissue (Figure 1, panel A-B, asterisks), the differential 
level of expression was found to be higher for CB2 (Figure 1B) than for CB1 
(Figure 1A). Evaluation of the relative expression carried out by quantitative 
image analysis (Aperio) on 13 separated tissue specimens having paired 
normal urothelium and tumor tissue represented on the same slides, 
revealed a significant higher staining score of CB2 in primary bladder cancer 
when compared to normal urothelium (Figure 1D). No significant differences 
were detected for the CB1 (Figure 1C).  
 
 
 
Figure 1. Expression of CB in human BCa. Representative immunoreactivity (scale bars: 500 µm) of 
cannabinoid CB1 (panel A) and CB2 (panel B) receptors from a representative patient with muscle invasive 
bladder carcinoma. Tumor lesion (asterisk) and normal urothelium (arrows) are indicated. Formalin-fixed 
paraffin-embedded sections from 13 different tumor specimens stained with hematoxylin and CB1 and 
CB2 antibodies (DAB) were analyzed with the Color Deconvolution analysis tool to quantify the DAB 
staining intensity. Staining score of CB1 (panel C) and CB2 (panel D) receptors were measured on the 
tumor lesion (grey bars) and normal epithelium (white bars) of 13 different patients in at least triplicate 
slides for each case. * p< 0.05 vs normal urothelium, Student T Test. Control staining in the presence of 
displacing CB1 and CB2 peptides are shown in Suppl. Fig. 1. Panel E: CB1 and CB2 gene expression 
analysis of primary muscle invasive BCa (N=5) by quantitative PCR analysis. Data are the mean±sd of 
quadruplicate fold-increase values over the paired non tumoral tissue (represented by the red dashed line). * 
p < 0.05 vs normal tissue.  
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The immunoreactivity of both CB1 and CB2 was found to be specific as 
confirmed by control staining in the presence of competing peptides (Figure 
2).  
 
Figure 2. Competing cannabinoid receptor staining. Immunohistochemical 
analysis of CB1 and CB2 receptor expression in human normal urothelium (U) and 
muscle invasive urothelial tumor (T), on the same section (magnification 200X).  
 
The presence of CB expression was also assessed and confirmed in five 
human specimens of primary bladder cancer collected perioperatively. 
Samples were analyzed by real-time PCR and displayed variable but 
consistently higher levels of CB2 when compared to normal urothelial tissue 
specimens from the same patient. CB1 was less expressed in the tumor and 
not differently expressed in comparison to normal tissue (Figure 1E). As 
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supportive data, expression of CB2 was analyzed in silico by interrogating 
the expression data available on bladder cancer patients collected by The 
Cancer Genome Atlas [43]. As shown in Figure 3 panel A, the expression of 
CB2 is significantly higher in invasive tumors. Expression of CB1 and CB2 
was also evaluated in bladder cancer cells by RT-PCR and WB analyses. 
Both bladder cancer RT4 and RT112 cell lines were positive for CB1 and CB2 
genes and expressed the CB2 protein to a similar extent. Conversely, CB1 
protein was only detectable in RT4 cells (Figure 3, panel B-C). 
 
 
 
Figure 3. Expression of CB in 
BCa tumors and cell lines.  
Panel A: in silico analysis of the 
expression of CB2 receptors in 
primary muscle-invasive bladder 
cancers. Data are expressed as box-
and-whiskers plots encompassing 28 
samples of T2a tumors, 37 samples 
of t2b tumors, and 137 samples of 
T3T4 tumors. Error bars represent 
the max value in each group.  
 
 
Panel B and C: Expression of 
cannabinoid receptors assessed by 
RT-PCR (A) and western blot (B) in 
RT4 (lane 1) and RT112 (lane 2) 
cells. The densitometric analysis of 
the relative bands for CB1 (66 bp or 
60kDa) and CB2 (141 bp or 40-45 
kDa), compared to reference 
housekeeping gene (β-Actin, 137 bp 
or GAPDH, 39 kDa), from three 
separated experiments  are shown 
(*** p<0.001 vs lane 1, Student’s T 
test). 
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Effect of the modulation of endocannabinoids system on human bladder 
cancer cell viability. 
I investigated the effect of the endocannabinoid anandamide (AEA) and the 
synthetic CB2 ligands JWH015 and JWH133 on the proliferation rate of both 
RT4 and RT112 cells.  AEA has greater affinity for CB1 than CB2, JWH015 
exhibits preferential agonist activity on CB2 [44,45], whereas JWH133 is 
considered CB2-selective [46]. Cells were exposed to increasing 
concentrations of the drugs over time, and cell viability was evaluated. As 
expected, AEA (20 μM) displayed a cytotoxic effect that peaked 48 hrs after 
exposure and allowed 26.4±1.9% and 50±3.6% residual cell viability on RT4 
and RT112 cells, respectively. Blockade of CBs with rimonabant (CB1 
antagonist) or SR144528 (CB2 antagonist) was tested in AEA-treated RT112 
cells. As shown in Figure 4A, data suggested that both receptors contributed 
to the early CB agonist-induced cytotoxic effects, since both CB1 and CB2 
antagonists partially rescued cell viability to approx 50% 24 hrs after AEA 
exposure. Only CB2 receptor blockade, however, prevented cell death at 
longer time points, as a max 75% increase of cell viability was evident 48 hrs 
after AEA exposure and stabilized over time (Figure 4A). Of note, cells 
exposed to AEA spontaneously regained normal proliferation activity after 5 
days (data not shown). Indeed, when cells were co-treated with AEA and 
oleoyl ethyl amide (OEtA), a specific inhibitor of FAAH enzyme, the cytotoxic 
effect of AEA potentiated (data not shown), suggesting that the reduced 
effects of AEA measured 5 days after exposure were mainly due to its 
degradation. In comparison to AEA, the CB2 specific agonist JWH015 
exhibited stronger and concentration-dependent antiproliferative activity on 
both RT4 and RT112 cell lines (Figure 4B), with the specific IC50 value 
calculated around 5 µM. Kinetics experiments then evaluated cell survival up 
to 96 hrs after JWH015. As early as 24 hrs after drug exposure, JWH015 
induced a significant decrease of cell viability that peaked four days after 
drug exposure, with a maximal inhibitory effect on RT4 and RT112 cell 
proliferation that amounted to 85±5% and 88±8% (p<0.001), respectively 
(Figure 4C). Conversely, AEA displayed a maximal inhibitory effect on cell 
survival by 30±5% (RT4) and 60±13% (RT112), measured 4 days post 
exposure. Under the same experimental conditions, JWH015 didn’tt induce 
any changes in the viability of human primary fibroblasts (Figure 4C). 
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Pretreatment with the CB2 antagonist SR144256 only partially counteracted 
the JWH015-induced (20 µM) antiproliferative effect by 25.6±3% (p<0.01 vs 
JWH015 alone) measured after 72 hrs incubation. To further support the 
CB2-mediated effect on cell viability, the agonists JWH015 and JWH133 
were tested on RT112 cells in the presence of a more potent CB2 antagonist 
(AM630). As shown in Figure 4, panel D-E, in both cases, cell viability 
measured 72 hrs after agonist challenge, was partially but significantly 
rescued in all the cytotoxic agonist concentrations. 
 
 
Figure 4. Effect of different cannabinoids (CB2-agonist) on bladder cancer cell proliferation.  
Panel A: Antagonistic effect of CB1-specific rimonabant (RIM, 10 µM) and CB2-specific SR144528 
(SR, 10 µM) drugs given simultaneously with anandamide (AEA, 20 µM) on CB1/CB2 agonist- 
induced toxicity of RT112 cells. Concentration of agonist and antagonists were chosen after 
preliminary experiments to determine optimal agonist cytotoxic effect and reliably measurable 
blocking effect of the antagonists when simultaneously co-administered to cells. *** p<0.001 vs 
AEA alone, 2-ways ANOVA, Bonferroni post test.  
Panel B: Dose-response citotoxicity on RT112 (black symbols) and RT4 (white symbols) cells, 
measured 72 hours post  JWH015. 
Panel C: Kinetics () of cytotoxicity after 20 µM JWH015 on both RT4 (white symbols) and RT112 
(black symbols) cells. The effect on normal fibroblasts is also shown (grey square symbols).   
Panels D and E: Effect of the CB2 antagonist AM630 (0.25 µM) on CB-2 agonist-induced RT112 
cell toxicity. Cells were pre-treated with AM630 for 30 min before exposure to either JWH015 (015) 
or JWH133 (133). Cell viability was assayed 72 hrs posr agonist challenge. * p< 0.05, *** p<0.001 vs 
agonist alone, 2-ways ANOVA, Bonferroni post test. 
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As shown in Figure 5, cell cycle analysis carried out by flow cytometry 48 
hours after CB2 agonist exposure demonstrated a significant higher 
accumulation of cells in the sub-G1 phase (28.2 ± 1%, p<0.01) compared to 
control cells (2.2 ± 0.9%). This finding was accompanied by an evident 
apoptotic phenotype, as the frequency of annexin-V+/PI+ cells increased 
6.7±0.3 (p<0.01) fold over untreated cells. The apoptotic phenotype was also 
confirmed by activated form of caspase 3 that accumulated over time (Figure 
5, panel A-B) following exposure to increasing concentrations of JWH015 
(Figure 5B). Caspase induction was not detectable earlier than 24 hrs after 
CB2 agonist exposure on RT112 cells, even in the presence of an autophagy 
inducer such as rapamycin (Figure 3C).  
 
Figure 5. Cell Cycle analysis.  
Panel A: representative FACS plots of annexin V/PI + cells induced by JWH015 exposure over time.  
Panel B: cell cycle analysis of RT112 cells treated with JWH015 (20 µM). The frequency of sub G1 phase 
population is shown. The table summarizes the % of cells for each phase. Histogram plots are overlaid with 
the interpolation model used to calculate the cell cycle phases (red line). 
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Cannabinoids were previously reported to promote cell death by modulating 
membrane sphingolipids and inducing autophagy in tumors [47,48]. 
I further assessed if CB activation in bladder cancer cells triggered 
autophagy, induced apoptosis secondary to the accumulation of Cer, and 
modified related sphingolipids. As shown in Figure 6B, in RT112 cells 
increasing concentrations of JWH015 induced conversion from the soluble 
form of LC3 (LC3-I) to the lipidated and autophagosome-associated form 
(LC3-II, a hallmark of autophagy) that peaked 24 hours after agonist 
exposure. Similar results were obtained with RT4 cells (not shown). This 
finding was also supported by LC3 quantitative immunostaining carried out 
on RT112 cells 24-48 hrs after JWH015 treatment (Figure 7, panel A-C). In 
RT112 cells, JWH015-mediated inhibition of mTORc1, evaluated as reduced 
phosphorylation of p70S6, was detected already 6 hrs after agonist 
stimulation and counteracted by an autophagy inhibitor (Figure 7D). 
Analysis of temporal AKT activation (Figure 6D) in JWH015-treated cells 
revealed that, after an initial upregulation detected 24-48 hours after drug 
exposure, AKT phosphorylation was significantly reduced at day 3 and 4, 
consistently with the cytotoxic effect. The up regulation of pAKT measured 
24 hrs after JWH015 challenge in RT112 cells was reversed (Figure 6E) by 
co-treatment with CB2 antagonist (SR144528) but not with CB1 antagonist 
(Rimonabant), suggesting a selective receptor-dependent effect. The effects of 
cannabinoids on the sphingolipids metabolism and in particular on Cer 
production were evaluated upon metabolic steady-state radiolabeling with [1-
3H]sphingosine, before and after exposure to JWH015. Independently of the 
basal cell membrane SL composition, which was different between the two 
cell lines tested, JWH015-treated cells exhibited 2-5-fold increased (p<0.001) 
Cer levels over the untreated cells baseline (Figure 6F). On the other hand, 
the levels of the pro-survival signal S1P were reduced by approximatively 
40% in both cell lines (p<0.001; Figure 6F). Exposure to JWH015 did not 
change the amount of sphingomyelin (SM) (Figure 7), thus, accumulation of 
Cer in JWH015-treated cells probably isn’t a consequence of SM hydrolysis. 
However, given that the prominent increase in the Cer levels detected in 
bladder cancer cells after JWH015 cannot be completely explained by the 
moderated rise of the S1P formation (Figure 6F), we carried out further 
investigations to quantify, before and after stimulation with JWH015, the 
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enzymatic activities of the intracellular and plasma membrane-associated 
glycohydrolases.  
 
 
Figure 6. Molecular events driving JWH015 citotoxicity. Representative Western blot experiments 
showing the effect of JWH015 on apoptosis and autophagy  mediators in RT112 cells. Data are expressed as 
fold change with respect to untreated control cells (dashed line) and are the means ± SD of three different 
experiments. °°° p<0.001 vs untreated cells baseline (dashed line); * p< 0.05 vs RT112. ** p< 0.01 vs RT112, 
2-tails Student’ T test. 
Panel A: JWH015-mediated (20 µM) induction of caspase 3 over time (0-96 hrs).  
Panel B: Dose-effect of JWH015 (1-20 µM) in inducing caspase 3 and LC3I-II 24-48 hrs post exposure.  
Panel C: JWH015-mediated (JW, 20 µM) induction of caspase 3 6-24 hrs after Exposure with or without 
addition of rapamycin (RA, 20 nM).  
Paned D: modulation of pAKT by JWH015 (20 µM) over time.  
Panel E: Effect of CB1 (rimonabant, Rim, 10 µM) or CB2 (SR14452, SR, 10 µM) antagonists when 
simultaneously administered to cells together with the CB2 agonist (JWH015, JW, 20 µM) upon 24 hrs 
incubation. Untreated (DMSO) control cells were tested both at time 0 and after 96 hrs of culture with similar 
results. A single experiment is shown as representative of three independent ones with similar results. 
Panel F: Ceramide (CER)/sphingosine 1-phosphate (S1P) rheostat levels in RT4 and RT112 cells treated 
with JWH015(20 µM). Cell lipids were metabolically labeled with [1-3H]sphingosine after 48 h JWH015 
incubation. Radioactive lipids were visualized by digital autoradiography and quantified with specific Beta-
Vision software.  
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Figure 7. Autophagy occurring in RT112 upon exposure to CB2 agonist.  
The conversion of the soluble form of LC3 (LC3-I) to the lipidated and autophagosome-associated form 
(LC3-II) was evaluated on RT112 cells upon 24 hrs exposure with JWH015 (20 µM) (Panel A) in 
comparison to the vehicle-treated control (Panel B). Fluorescence microscopy analysis was carried out by 
using a specific LC3 antibody followed by alexa-green labeled secondary pAb. Nuclei were labeled with 
DAPI (blue). Scale bars= 4 µm. The insoluble form of LC3 is evidenced by more intensely and condensed 
green-labeled intracellular localizations. Quantification of LC3 puncta+ cells is shown in Panel C. The 
percentage of cells with more than 5 LC3 punctae was calculated by counting at least 6 fields. Data are the 
mean±sd of quadruplicate counts in two independent experiments. Panel D: immunoblot analysis of 
p70SP phosphorylation in RT112 cells measured 6 hrs after JWH015 challenge (20 µM) with or without 30 
min pre-treatment with rapamycin (20 nM) or bafilomycin (100 nM). 
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As summarized in Table 1, the activity of the enzyme devoted to 
sphingomyelin (SM) catabolism, namely sphingomyelinase (SMase) did not 
increase following JWH015 exposure, confirming that SM hydrolysis did not 
contribute to the build-up of ceramide. In addition, the plasma membrane-
associated glycohydrolases GBA1/GBA2, β-Galactosidase and β-
Hexosaminidase displayed a significant increment in the enzymatic activity 
48 hrs after JWH015 exposure (Table 1). This JWH015-mediated effect on 
glycohydrolases appeared to be preferential at the plasma membrane level, 
since the same enzyme activities measured in the total cell lysate did not 
change (Table 2). Along with this, I also assessed Cer synthase (CERS) gene 
expression by qPCR and found that in JWH015-treated cells the levels were 
significantly higher in RT112 (+200%) as well as in RT4 (+120%) cells 
compared to controls (not shown), indicating additional contribution via de 
novo synthesis to the final Cer level in JWH015-treated cells.  
 
 
Table 1. Plasma-membrane associate glycohydrolases measured in RT4 and RT112 cells treated 
with JWH015. Cells were treated or untreated for 48h with 20 μM JWH015 and subjected to enzymatic 
assays. The activity associated with the cell surface was measured directly on living cells. Data are expressed 
as picomoles of formed metabolite per milligram of cell protein per hour and are the mean ± SD of at least 
three separate experiments. Comparisons between groups were made using Student’s t test. *p<0.005 vs 
untreated cells.  
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Table 2. Enzyme activity in total cell lysate measured in RT4 and RT112 cells treated with 
JWH015. Cells were treated or untreated for 48h with 20 μM JWH015 and subjected to enzymatic assays. . 
The activity associated with the total cell lysate was evaluated as described above. Data are expressed as 
picomoles/nanomoles of formed metabolite per milligram of cell protein per hour and are the mean ± SD 
of at least three separate experiments. Comparisons between groups were made using Student’s t test.  
° p<0.005 vs RT4,  *p<0.005 vs untreated cells,  §: picomoles per milligram of protein per hours. 
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Bladder cancer cell motility is modulated by cellular GSL 
I found a significant differential expression of some GSL (Figure 8) between 
RT4 and RT112 cell lines. Previous reports had already demonstrated how 
cellular GSL, in particular gangliosides, may dramatically change during 
differentiation and malignant transformation promoting cellular motility [49]. 
As depicted in Figure 8A, the levels of the globotriesosylceramide, Gb3, 
previously described as cell motility-promoting sphingolipid [27], was found 
15-fold higher (p<0.001) in RT112 cells than in RT4 cells. Conversely, RT4 
cells showed a 5-7-fold higher levels (p< 0.01) of both the cell migration-
inhibiting ganglioside GM3 [27,49,50] and of glucosylceramide (GlcCer) 
respectively (Figure 9A). In addition, the lower levels of GM3 detected in 
RT112 cells compared to RT4 cells strongly correlated with the increased 
enzymatic activity (+55.4±5%, p<0.01) of the specific sialidase Neu3 (Table 
1), which is devoted to hydrolyze gangliosides, such as GM3, at the cell 
plasma membrane level. Furthermore, we detected a 4-fold increase (p< 
0.05) in the expression levels of the GM3 synthase gene (SAT1) in RT4 cells if 
compared with RT112 (not shown).  
 
 
Figure 8. Representative TLC showing lipid composition of BCa cells before and after JWH015 
treatment. After metabolic labeling with 2h pulse of [1-3H]sphingosine, RT4 (lanes 1–2) and RT112 (lanes 
3-4) cells were chased with vehicle (lanes 1 and 3) or 20μM JWH015 for 24 h (lanes 2 and 4). Cellular lipids 
were then extracted and subjected to phase separation as described in Materials and Methods. The total 
lipid extracts (panel A), spotted as equal amount of total radioactivity and equal volumes of partitioned 
lipids in the aqueous (panel B)  and organic (panel C) phase, corresponding to same amount of total cell 
lipid radioactivity, were separated by HPTLC and visualized by digital autoradiography. Radioactive lipids 
were identified by using the appropriate standards: ceramide (Cer), glucosylceramide (GlcCer), 
phosphoethanolamine (PE), globotriaosylceramide (Gb3), sphingomyelin (SM). 
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The different GSL pattern between RT112 and RT4 cell lines were, in turn, 
associated with different functional features in terms of cellular motility. As 
depicted in Figure 9, RT112 and RT4 cells, independently of their 
comparable proliferation rates (not shown), displayed a differential motility. 
In a wound-healing assay (Figure 9, panel B-G), we found that RT112 cells 
reconstituted more than 70% of the scratched area within 48 hrs (Figure 9, 
panel D-E-F), while, in the same time frame, RT4 cells only populated 5% of 
the free available surface (Figure 9, panel B-C-F)  The invasivity features of 
RT112 cells were also markedly different from the RT4 cells, as 
demonstrated by a classical matrigel-based invasion assay (Figure 9G). To 
sum up, considering the nature of the constitutive GSL, the associated 
metabolic enzymes, and the differential cell mobility and invasivity, RT112 
and RT4 cells can reasonably be considered as models of high- and low-
grade malignancy, respectively. In addition to these evidences, along with the 
recent findings that demonstrated the strong link between plasma 
membrane GSL and the activation of ERM proteins in driving cancer 
progression mechanisms [51,52], I showed that the levels of phospho-ERM 
detected in RT112 cells were significantly higher compared to RT4 (Figure 
9H), suggesting a cytoskeletal rearrangement in high-grade bladder cancer 
cells. Previous data [53] demonstrated that the phosphorylation level of ERM 
was strictly linked to the level of S1P. Consistently with this, the content of 
S1P we measured in high-motility RT112 cells was 3-fold higher than the 
one in low-motility RT4 cells (3.8±0.56 vs 1.43±0.36 nCi mg-1; p<0.01); in 
addition, the sphingosine kinase 1 (SK1) was upregulated in both gene 
expression (5-fold) and enzymatic activity (891±94 vs 283±71 pmoles hour-1 
mg-1; p<0.01) in RT112 cells compared to RT4 cells. Finally, in order to 
directly relate the GSL metabolism with cell motility, RT112 cells were 
pretreated either with an inhibitor of GSL synthesis (AMP-dNM) or a 
migration-inhibitory GSL (GM3) before measuring the cell migration in the 
scratch assay. As shown in Figure 9I, both AMP-dNM and exogenous GM3 
were able to significantly reduce the motility of RT112 cells. 
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Figure 9. Differential GSL composition and motility between high and low grade BCa cells. 
Panel A: Sphingolipid composition of RT4 and RT112 cells. Cell lipids were metabolically labeled with [1-
3H]sphingosine at the steady-state. Lipids were then extracted separated by HPTLC, visualized by digital 
autoradiography and quantified with specific Beta-Vision software. Data are expressed as the percentage of 
total radioactivity incorporated into sphingolipids and are the means ± SD of three different experiments. * 
p< 0.05 versus RT112. ** p< 0.01 versus RT112.  
Panels B-E: Representative pictures of wound-healing assays in either RT4 cells at T0 (panel B) and 48 h 
after scratch (panel C) or RT112 cells at T0 (panel D) and 48 h after scratch (panel E). Wound edges were 
artificially highlighted by drawing a black line.  
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Panel F: Quantification of cell migration  evaluated as % of cell-covered area at 24 h (gray bars) and 48 h 
(black bars) compared to the cell-free wound area at time 0 (white bars). Data are the mean±sd of three 
independent experiments done in triplicate. ** p<0.01 vs RT4 cell, ANOVA, Dunnett’s T test.  
Panel G: invasion assay on RT4 and RT112 cells. Data ate expressed as number of migrated cells through the 
pores with or without the presence of matrigel. The percent of invasion thru the matrigel is show in the panel 
inset. Data are the mean±sd of quadruplicates from 2 independent experiments. *** p< 0.01 vs RT4 cells.  
Panel H: Phospho-ERM WB quantification on low-motility (LM, RT4) and high-motility (HM, RT112) cells. 
EZRIN, GAPDH and β-Actin proteins were used as control.  
Panel I: Cell motility quantification of RT112 cells in the presence of GSL metabolism modulators evaluated 
as % of re-populated scratched area, compared to control (CONT). Wounded RT112 cultures were incubated 
with vehicle (DMSO), AMP-dNM (0.4 µM) or exogenous GM3 (25-50 µM) for 24 hrs. Data are the mean±sd 
of three experiments done in triplicate. 
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Previous reports associated cannabinoids with reduced metastatic and 
invasive behaviors in cancer, both in vitro and in vivo [54]. We then evaluated 
the effect of non-cytotoxic concentrations of JWH015 on the migration 
capability of high grade RT112 cells. As shown in Figure 10, RT112 cells were 
prevented from migrating upon exposure to escalating doses of JWH015. In 
particular, 1 μM JWH015 significantly inhibited by approx. 50% the 
reconstitution of the cell monolayer (Figure 10, panel D-G) 24 hours after 
stimulation, as compared to untreated control cells (Figure 10, panel B-G). The 
maximal effect was achieved with the highest JWH015 concentration (20 μM) 
and accounted for almost 90% inhibition (Figure 10, panel E-F-G). This effect, 
however, was accompanied by an increase in the frequency of apoptotic and 
necrotic phenotype, which accounted for 40±3% in cells treated with 20 μM 
JWH015, compared to 3±2% in 1 µM-treated cells or 3.5±2% in control cells 
(p<0.01). The functional effect on the migratory properties in aggressive RT112 
cells was accompanied by a change in the levels of the motility-promoting 
globoside Gb3, which reduced after JWH015 treatment (Figure 10H, p<0.01) in 
RT112 cells, while it remained unchanged in low motility RT4 cells. As 
expected, both in high grade (RT112) and low grade (RT4) cells, agonist-
mediated CB2 activation increased the level of the Cer precursor GlcCer 
(Figure 10H).  
To further test the anti-migratory effects of cannabinoids we assayed the 
level of phospho-Src in its inactive state. The activation of the c-SRC protein 
is associated with enhanced migratory features, cell transforming potential 
and cancer progression [55]. As shown in Figure 10I, the inactive form of c-
Src, which is phosphorylated in Tyr-530, was consistently up-regulated over 
time in cells treated with the CB2 agonist JWH015. The effects of JWH015 
on cell migration was partly reverted by the pharmacological inhibition of 
GSL metabolism, which increased the cell motility (Figure 10J) and reduced 
the inactive form of p-Src (Figure 10K). 
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Figure 10.  Effect of JWH015 treatment in high motility RT112 cells.  
Panels A-F: Representative pictures of RT112 wound healing assay evaluated 24 hrs post scratch. Wound 
edges were artificially highlighted by drawing a black line.  
Panel G: Cell migration was quantified as % of cell-covered area at 24 h (black bars) compared to the cell-
free wound area at time 0 (white bars). Data are the mean±sd of three independent experiments in 
triplicate. ** p<0.01 vs T0, ANOVA, Dunnett’s T test.  
Panel H: Levels of measured GSL (GM3, Gb3, and GlcCer) in RT4 and RT112 cells after exposure to 
JWH015 (1 µM) for 24 h. Data are the mean±sd of three independent experiments and expressed as fold 
chance over the level measured in untreated cells and indicated by the dashed line. * P<0.05 vs RT4, 
ANOVA, Dunnett’sT test.  
Panel I: immunoblotanalysis of inactive c-Src (p-Src Tyr527) 24 and 48 hrs after JWH015 (1 µM) exposure 
in RT112 cells. Similar results were obtained in two other independent experiments.  
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Panel J: Effect of GSL synthesis inhibition by AMP-DNM (0.4 µM) on JWH015 (1 µM) -modulated 
RT112 cell migration evaluated as % of re-populated scratched area. Data are the mean±sd of 
quadruplicate values.  
Panel K: Immunoblot analysis of inactive c-Src (pSRC Tyr527) in RT112 cells treated with JWH015 (1 
µM) with or without AMP-DNM (0.4 µM). The calculated fold-increase of band density (mean±sd, n=4) is 
shown above the panel. Both low and high exposure blots are shown.  
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Effects of the CB2 agonists on a murine model of an orthotopically 
implanted urothelial cancer 
In order to gain a formal proof of concept that local exposure to CB2 agonists 
may prevent tumor growth in vivo, we used a relevant murine model of an 
orthotopically implanted urothelial cancer. As shown, intravesical 
instillations of JWH015, started three days after mucosal tumor 
implantation, significantly delayed the onset macro-hematuria, a specific 
symptom of tumor uptake and reduced the frequency of tumor-positive 
animals (Figure 11A). Terminal evaluation of the tumor load evaluated as 
bladder weight measured 2 weeks after tumor implantation demonstrated 
that intravesical instillations successfully reduce the tumor burden 
compared to vehicle-instilled animals (Figure 11B). The data support the 
effect of the CB2 agonists in inhibiting both tumor progression and growth.  
 
 
 
Figure 11. Effect of JWH015 on orthotopic bladder tumor uptake and growth in vivo.  
 
Panel A: Frequency of macro hematuria-positive animals. Animals were engrafted with BCa cells as 
previously describe in Matherials and Methods. Three days after tumor instillations mice were treated 
intravesically with vehicle (n=9) or 20 µM JWH015 (n=6). Treatments were repeated other two times 4 
days apart.  
 
Panel B:  quantification of tumor burden evaluated as increment of bladder weight. Data are normalized 
and expressed as the mean±ds of mg bladder over g body weight. Horizontal dashed line represent the 
normality cut-off of bladder weight in naïve, untreated animals. 
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Figure 12. Histological evaluation of tumor  bearing bladders. Representative image of a bladder of 
vehicle-treated (Panel A) and JWH015-treated animals (Panel B). Tumor lesions are indicated by the circle. 
Scale bars= 0.5 mm 
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My study suggests CB2 as a putative novel target for innovative treatments 
and diagnostic/prognostic tools in BCa., I describe also previously 
unrecognized links between the endocannabinoid system and the 
glycosphingolipid pathway, as CB2-mediated modulation of cancer cell 
proliferation are conveyed by specific lipidic signals that also control cell 
motility and malignancy of urothelial cancer cells. 
 
CB2 receptor as potential target in BCa 
Recent data describe CB1 and CB2 receptors in all layers of the normal 
human bladder [18,20]. It Has already been described for other tumor types 
[56,57], we found that in primary BCa, the expression of CB2 is consistently 
higher in the neoplastic lesion, when compared to paired normal urothelial 
and stromal counterparts. This finding may support the specific use of CB2 
as target of therapeutic and diagnostic approaches [58]. 
My results also demonstrate that CB2 receptors which are expressed in 
bladder cancer cells are functional, as indicated by the effect of the CB2-
selective synthetic agonists on cellular functions, which was partially 
prevented by CB2-selective antagonism, but not by a CB1 antagonist. 
Notably, and consistent with previous findings [54,59,60], the JWH015-
induced arrest of proliferation appears to be selective for tumor cells, while 
no significant effects are detected if the cells present a low proliferation rate, 
such as normal human fibroblasts, upon exposure to the CB2-agonist. 
Hence, stimulation of CB2 may be coupled to the activation of signaling 
pathways that are differently regulated between transformed and non-
transformed cells [54]. I cannot exclude the involvement of a third related 
receptor, such as the GPR55, which may also interact with JWH015 [61,62]. 
This receptor is however contradictory reported to be associated with signals 
that promote either cancer cell proliferation or antiproliferative effects 
[63,65]. Further studies are needed to elucidate the role of GPR55 also in 
bladder cancer. 
 
CB2-mediated cytotoxic mechanisms in BCa cells 
Previous reports [48,54,65] demonstrated that tumor cell autophagy is 
induced by cannabinoids as an early event. I found that BCa cells react to 
the cannabinoid-induced stress by initially activating autophagy as defective 
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survival signal that is eventually taken over by the apoptotic response. Also, 
some molecular events, such as mTORC1 inhibition, predisposing the 
autophagy machinery are occurring before the cannabinoid-mediated 
caspase 3 activation, confirming that cellular and possibly defective 
autophagy, is indeed preceding the JWH015-induced cytotoxicity of bladder 
cancer cells. Furthermore, Cer-mediated inhibition of the pro-survival signal 
Akt is a well-recognized mechanism of mTORC1 inactivation and apoptosis 
conversion [48,66].. In my experimental setting, however, this effect is 
preceded by a transient increase in the phosphorylated form of Akt, 
indicating an initial possible activation of this system. These apparently 
contrasting results may be partly explained by either a cellular homeostatic 
loop that transiently switches on in an attempt to maintain Akt activity upon 
its inhibition, as it has been previously described [56], or by speculating a 
possible effect of the JWH015 compound on the GPR55 receptor that is 
reported to upregulate Akt in other tumors [63,64,67].  
To better understand the mechanism of action of CB2-mediated apoptosis in 
bladder cancer cells, I investigated the role of sphingolipids metabolism in 
the modulation of cell survival/death pathways. Cer, indeed, is well known 
pro-apoptotic lipid, which is described to act as a second messenger of the 
cannabinoid-mediated actions in various model systems [68]. CB1 
activation, for instance, induces Cer accumulation in primary astrocytes and 
glioma cells through both SM hydrolysis and de novo synthesis [28,69]. 
Recently, CB2 activation has been shown to induce cell apoptosis through 
the stimulation of Cer de novo synthesis in a number of human tumors, 
including glioma [28,69], leukemia [70], and pancreatic cancer [71]. 
The mechanisms involved in the CB2–mediated induction of Cer are still 
largely unknown. my data demonstrate that CB2 activation may indeed 
stimulate Cer synthesis also in bladder cancer cells. The molecular event 
underlying Cer accumulation upon exposure to CB2 agonists is most likely 
not due to sphingomyelin hydrolysis, whose cellular level remains 
unchanged, but are rather mediated by reduced metabolism of S1P. Cer is 
produced by dephosphorylation of S1P, operated by two specific 
phosphatases (SPP1 and SPP2), to sphingosine, which eventually is 
converted to Cer by CERS. In addition, conversion of the sphingosine to S1P 
operated by the sphingosine kinases could also play a pivotal role in this 
process [72]. We investigated the role of different enzymes involved in the 
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GSL metabolism to analyze the biochemical pathways leading to Cer-induced 
apoptosis in bladder cancer cells upon exposure to cannabinoids. Like Cer, 
S1P may also act as a second messenger in the regulation of cell 
survival/death pathways, with an opposite, anti-apoptotic effect [31]. Thus, 
conversion of S1P into sphingosine and eventually Cer shifts the ratio 
between anti-apoptotic to pro-apoptotic signals (namely S1P and Cer) 
towards cell death. The increase of Cer, with the concomitant reduction of 
S1P, perfectly reflects the well-known sphingolipid rheostat which controls  
cell proliferation/apoptosis. In fact, a high level of Cer associated with a low 
amount of S1P is usually resulting in cell growth arrest, whereas the 
opposite situation corresponds to an increased cell proliferation [31]. The 
large increase in Cer content that I measured is however not completely 
attributable to the moderate, but significant, reduction of S1P. Since Cer 
may also  derive from de novo biosynthesis as well as GSL catabolism, I 
demonstrated that the CB2 agonist JWH015 triggers Cer accumulation also 
via the known mechanism [73], which implies the sequential activation of 
different GSL-converting glycohydrolases located in the cell membrane. 
Overexpression of Neu3 and production of LacCer have been demonstrated 
to provide antiapoptotic effects in tumors [74,75]. In contrast, I detected a 
significant increase of Neu3 activity after CB2 activation. This effect may be 
explained either by a CB2-mediated apoptotic signal that originates from 
Neu3-mediated GM3 hydrolysis and ends up to Cer via activation of 
downstream glycohydrolases, or by an ineffective attempt of the bladder 
cancer cells to survive by increasing the levels of LacCer. Thus, my data 
support the hypothesis that, in bladder cancer cells, the initial accumulation 
of the lipid ceramide, in response to JWH015 treatment, is due to multiple 
and coordinated series of biochemical pathways leading to apoptosis 
activation.  
 
Role of GSL metabolism in BCa cell motility and its modulation by CB2 
engagement 
The models which has been shown of bladder cancer are characterized by 
significant differences in the GSL patterns, particularly reminiscent of the 
described differential GSL composition reported for invasive and papillary 
bladder cancer [27]. I show that bladder cancer cells expressing high Gb3 
and low GM3 gangliosides in fact display enhanced cell mobility, which 
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characterizes the RT112 cells as a suitable model for invasive bladder 
cancer. This feature is further reinforced by the evidence demonstrating that, 
in high-motility bladder cancer cells (RT112), a robust inverse correlation 
exists between the cellular levels of S1P [53] and up-modulated phospho-
ERM proteins. Phosho-ERMs have previously been recognized to play a 
pivotal role in driving cancer progression mechanisms through its increased 
levels that control the cytoskeletal rearrangement [51,52].  
Along with these evidences, I have shown that the agonist-mediated 
activation of CB2 receptors in high grade bladder cancer cells have a 
profound impact on GSL, which are components of the plasma membrane 
that dramatically change during cell differentiation and malignant 
transformation [76]. The molecular mechanisms involved in the downstream 
activation of CB2 receptor appear complicated and further studies are indeed 
necessary. Still, I show that cell motility in bladder cancer cells, a hallmark 
feature of aggressive cancer, may be controlled by agonist-mediated CB2 
activation, in a way that possibly interferes with the FAK-Src [55] pathway. 
Consistently, I have detected a significant increase of the inactive form of p-
Src after CB2 activation, which resulted in reduced cell motility. This effect, 
as well as the activation of programmed cell death, is likely mediated by 
early events that impact on GSL metabolism. In attempt to illustrate a 
molecular model, as depicted in Figure 13, it’s reasonable to suggest that, 
upon agonist-induced CB2 activation in high grade bladder cancer cells, a 
dual action inhibiting the sphingosine kinase enzyme and upregulating the 
ceramidase takes place. This in turn favors a reduction of S1P and an 
increase of Cer that shift the balance of the cellular rheostat towards 
apoptosis and cell cycle arrest. On the other hand, the plasma membrane-
associated enzymatic hydrolysis of GSL is activated and produces a signaling 
cascade that may modulate cytoskeletal changes via p-ERM and cell 
migration via Src. Into this picture though, it is important also to consider 
the already reported receptor-independent effects of cannabinoids [77], 
which may play an important role in our system. 
The present study, however, strongly associates the anti-metastatic 
properties of cannabinoids, which are described in the recent literature, [78-
81], with a molecular mechanism involving CB2 contribution that implicates 
GSL metabolism. This finding, together with the in vitro antiproliferative 
effect, the in vivo efficacy on tumor progression, and the tumor-specific up-
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regulation of CB2 in primary bladder cancer may play a role in the 
identification of novel therapeutic and diagnostic targets for treating bladder 
cancer. In addition, the use of non psycho-tropic cannabinoid agonists may 
warrant further studies to implement a more effective adjuvant treatment in 
transitional BCa aimed to prevent both tumor recurrence and progression.  
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